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The construction of polypropionate stereotriads in the synthesis of many non-aromatic 
polyketide natural products has typically been achieved through the “Roche ester” approach. This 
process starts with one of the stereocenters purchased as the Roche ester, followed by multiple 
redox and protecting group manipulations and only one carbon-carbon bond-forming aldol or 
crotylation reaction to attain the other two stereocenters of the stereotriad. Motivated by a desire 
for a more direct and rapid synthesis of these stereotriad constructs, we have built upon previous 
group methodology to develop a new approach utilizing a three step sequence of alkyne 
silylformylation-crotylation-Tamao oxidation. This strategy was first utilized in the synthesis of 
the C1-C9 fragment of the epothilones, and then this route applied to the synthesis of a C6 methyl-
modified analog of epothilone B. We have also pursued the synthesis of versatile polypropionate 
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Chapter 1: Introduction 
1.1  Introduction 
Non-aromatic polyketide natural products are a pharmaceutically important class of 
compounds due to their often high levels of biological activity. A number of these compounds 
have been identified as potent antitumor agents and have thus been highly pursued for use as 
therapeutic agents. By binding to tubulin, the molecules disrupt microtubule dynamics, inhibiting 
mitosis and leading to cell death. Due to limited access to some of these important natural products 
or a need for innate structural modifications to improve their pharmacological properties, the use 
of synthetic chemistry has become paramount for the further development of a number of 
polyketides as therapeutic agents. 
 
Figure 1.1 Representative Antimitotic Polyketides Containing Polypropionate Stereotriads 
In the Leighton group, we are interested in developing new methodologies and strategies 
for highly efficient and scalable access to stereochemically complex polyketide compounds.1–11 
One common structural motif that has been found in a variety of natural products is the 
polypropionate stereotriad, with alternating methyl, hydroxyl, methyl stereocenters (Figure 
1.1).12,13 This thesis will focus broadly on the development of a new approach to the rapid synthesis 
of these polypropionate stereotriads. This new strategy will first be discussed in the context of the 
synthesis of the C1-C9 fragment of the epothilones and the utilization of this synthesis to obtain a 
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C6 methyl-modified analog equipped with linker functionality, followed by generalization of our 
approach for the synthesis of versatile polypropionate building blocks.14 
1.2 The Epothilones 
1.2.1 Introduction: Discovery and Biological Activity 
The epothilones are a family of cytotoxic natural products that were first isolated from the 
myxobacterium Sorangium cellulosum in 1987.15,16 While initially of some interest for their 
antifungal properties, these compounds attracted much more attention from the scientific 
community in 1993 when they were found to exhibit potent taxane-like antitumor activity.17 
 
Figure 1.2 Structures of the Epothilones and Taxol 
Epothilones A (Epo A, 1.1) and B (Epo B, 1.2), have been found to act via the same 
microtubule-stabilizing mechanism of action as taxol (1.3), the first therapeutic agent with this 
mechanism to obtain FDA approval (Figure 1.2). While Epo A exhibits similar activity to taxol in 
a number of cancer cell lines, Epo B is about tenfold more potent in the same cell lines.18 Though 
they act at the same microtubule binding site, the epothilones are significantly more active than 
taxol for inhibiting the growth of multidrug-resistant (MDR) cancer cell lines. In taxol-resistant 
cancer cell lines that overexpress phosphoglycoprotein 170 (P-gp), epothilones A and B are able 
to maintain almost full anti-proliferative activity because they are poor substrates for the P-gp 
efflux pump.17,19 Epothilones have also been shown to retain activity in cancer cell lines that have 
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developed taxol-resistance due to particular tubulin mutations, which is the another main 
mechanism of taxol-resistance.20 Besides activity, the epothilones have the practical advantage of 
exhibiting increased solubility relative to taxol, meaning they would not require clinical 
formulation vehicles such as Cremophor which has been implicated for some of taxol’s clinical 
side effects.21 Due to these advantages over taxol, the epothilones have become highly attractive 
targets for drug discovery efforts and total synthesis efforts. Over 30 total syntheses of Epo A and 
B have been reported, as well as extensive studies of the structure-activity relationship (SAR) of 
the epothilones. As a result of these efforts, a number of epothilone-derived compounds have been 
advanced to clinical trials as potential anticancer drugs. This thesis will give only a broad overview 
of these topics, as they have been extensively reviewed.18,22–34 
1.2.2 Structure-Activity Relationship (SAR) and Clinical Development 
Due to the relative simplicity of the epothilone structure relative to taxol, thorough 
exploration of the structure-activity relationship of these compounds has been possible through 
semi-synthesis and diverted total synthesis. Most of this analog work has been undertaken by the 
Nicolaou22 and Danishefsky23 groups, along with some important findings from research groups 
at pharmaceutical companies such as Novartis25,35, Schering36, and Bristol-Myers Squibb37. For 
the purposes of discussing the SAR of these compounds, the epothilone structure can be broken 
into four sectors (Figure 1.3): the lactone, the densely functionalized polyketide fragment from 
C1-C8, the epoxide-containing fragment from C9-C14, and the heterocycle-containing side chain 




Figure 1.3 Structure-Activity Relationship for Epothilones 
Some of the early work that was done in developing semi-synthetic analogs demonstrated 
that the lactone could be replaced by a lactam.37 Though there were ultimately no stability issues 
found for the lactone-containing natural epothilones in human plasma, this effort by Bristol-Myers 
Squibb researchers was motivated by the hydrolytic instability of these compounds in rat plasma. 
The lactam analog, ixabepilone (1.4), was advanced to clinical trials and has become the only 
epothilone thus far to obtain FDA approval. Although approved for the treatment of breast cancer, 
this compound has been shown to be a better substrate for the P-gp efflux pump than the natural 
epothilones, so it does not exhibit the same potent activity as epothilones against many MDR 
cancer cell lines. The unsatisfactory activity against MDR cancers and reports of serious side 
effects, such as hematological toxicity and peripheral sensory neuropathy, have caused researchers 
to continue seeking epothilone analogs with improved therapeutic properties. 
Few structural alterations have been tolerated in sector II (see figure 1.3). Replacement of 
the C3 hydroxyl group with a cyano group, conversion to an α,β-unsaturated lactone, or removal 
of C3 functionality result in analogs that retain most of the activity of the parent compound. 
However, biological activity is significantly reduced with most other changes to C3-C5, including 
inversion of C3 stereochemistry, oxidation of C3, reduction of C5, and replacement of C4 with a 
nitrogen.30 Any changes to the stereochemistry in the C6-C8 propionate-derived stereotriad have 
significantly diminished the microtubule binding activity; however, it has been shown that linear 
extension of the C6 methyl into an allyl or propyl group is well tolerated.36,38 Overall, modification 
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of the polyketide sector has been detrimental to the activity in most cases, with the stereochemistry 
of the C6-C8 stereotriad being critical for cytotoxicity. 
The structure of sectors III and IV have been found to be the most tolerant to structural 
changes, and in some cases these areas have been modified to produce analogs with increased 
potency or improved therapeutic properties. In sector III, it has been found that the epoxide is not 
vital for activity. Replacement by an alkene, cyclopropane, or aziridine (including both cis- and 
trans- isomers) are all tolerated changes which result in activity similar to the natural products, 
provided the stereochemistry is maintained. Replacement with a diol or acetonide-protected diol 
results in reduced activity. Given the SAR data, it has been postulated that the epoxide serves a 
conformational/structural role rather than acting as a hydrogen-bond acceptor or reactive 
electrophile.30 
 
Figure 1.4 Selection of Epothilone Analogs Advanced to Clinical Trials 
As indicated by the higher potency of Epo B relative to Epo A, methyl substitution of the 
epoxide leads to higher activity. Replacement of one hydrogen of the methyl with a fluoride, 
chloride, or methyl is tolerated, but larger groups decrease activity. Replacement of the methyl 
with a trifluoromethyl group was investigated by the Danishefsky group, and it was found to 
decrease toxicity and broaden the therapeutic index of analogs, ultimately leading to two promising 
drug candidates, fludelone (1.5) and isofludelone (1.6).39,40 
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Other modifications of sector III, including enlarging or decreasing the size of the 
macrocycle and attempting to stabilize the structure by incorporating aromatic rings within the 
alkyl chain, caused either a decrease or a complete loss of activity. Later endeavors toward 
structural stabilization through installation of unsaturation in the C9-C11 portion resulted in lower 
activity in the case of a conjugated diene (C10-C11); however, installation of a trans double bond 
at C9-C10 to form the skipped diene resulted in increased potency relative to the natural products. 
This finding has been incorporated into some of the analogs developed by the Danishefsky 
group which have been advanced to clinical trials.40,41 The most promising of these compounds is 
isofludelone (1.6), which is currently in Phase I clinical trials. The modifications made in 
developing this analog started with replacement of the epoxide with an alkene, which reduces 
activity but is thought to decrease toxicity. The next change was the installation of unsaturation at 
C9-C10, which improved the potency and biological stability. As mentioned previously, 
installation of the trifluoromethyl group helped to decrease the toxicity and broaden the therapeutic 
index. Finally, replacement of the of the thiazole ring in the side chain with an isoxazole increased 
the efficacy and stability. Isofludelone has been found to result in sustained tumor suppression in 
vivo for certain breast and ovarian cancer cell lines, and growth suppression of other cancer cell 
lines including fast-growing SK-NAS brain tumors.39,40 
Extensive modification of the heterocyclic side chain of sector IV has revealed that some 
extension of the thiazole methyl is tolerated, including substitution with hydroxyl and amino 
groups. Changes to the heterocycle itself are tolerated for pyrazole, tetrazole, and oxazole analogs, 
and pyridine analogs are tolerated when the nitrogen position is ortho relative to the vinyl linker. 
Thorough investigation by the Nicolaou group showed that rigidification of the side chain with 
fused biaryl moieties was tolerated for benzothiazole, benzoxazole, benzimidazole, and quinolone 
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groups. In fact, these analogs typically showed an increase in potency relative to the natural 
products, with the benzimidazole exhibiting the most pronounced effect.42 Independent 
investigation of analogs of this type by researchers at Schering AG has resulted in a compound 
with a benzothiazole side chain advancing to clinical trials as the first fully synthetic epothilone 
analog. In addition to the side chain modification, the structure of sagopilone (1.7) also deviates 
from Epo B in the substituent at C6, with an allyl group in place of the methyl found in the natural 
product. These changes resulted in a compound that exhibited higher potency in vitro than the 
natural products against a variety of drug-sensitive and MDR cell lines.38,43 
 While the information presented in this section summarizes only some of the most 
important SAR findings, it should be clear that there have been extensive efforts from a number 
of research groups to amass this data. All of this accumulated information has led to the 
development of a number of potential drug candidates, with eight epothilone-derived compounds 
advancing to clinical trials, and one achieving FDA approval thus far. While the clinical 
development of some of these compounds has since been terminated, some of the most promising 
candidates are still being evaluated, namely Epo B (1.2), sagopilone (1.7), and iso-fludelone (1.6). 
In all of this investigation, it has been revealed that the polyketide portion of the molecule 
(sector II) is fairly critical for potency while the other sectors are open to some modification 
towards obtaining optimal therapeutic properties. In fact, with the exception of 1.7, all of the 
candidates that have advanced to the clinic retain the C1-C8 portion of the natural products. In the 
case of sagopilone, the stereochemistry is maintained and the deviation is simply a two-carbon 
extension of the C6 methyl group. Since this polyketide portion is the most stereochemically dense 
fragment of the epothilones and its synthesis most broadly useful, our group has become interested 
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in applying our polyketide methodology to the development of a more direct and efficient route 
towards the C1-C9 fragment.  
1.2.3 Retrosynthesis and Overview of Synthetic Strategies 
Chemists quickly began their efforts towards the synthesis of these compounds once the 
absolute stereochemistry of natural epothilones Epo A and B had been determined via X-ray 
structural analysis and reported in 1996.15 There have now been over 30 complete and formal 
syntheses of these natural products reported, with most going through epoxidation of the Epo C 
(1.8) or Epo D (1.9) precursor to obtain Epo A or Epo B (Scheme 1.1). Most of the later syntheses 
also depend on the same disconnection strategies and key fragments that were utilized in the 
initially reported syntheses. The first synthesis of Epo A was reported by the Danishefsky group 
in 1996,44 followed within months by the Nicolaou45 and Shinzer46 groups. Scheme 1.1 shows 
popular disconnection strategies in building the epothilone structures, with the most common ring-
closing strategies indicated more specifically. Macrolactonization via the Yamaguchi protocol47 
has become perhaps the most favored ring-closing method, due to selectivity issues with the ring-
closing metathesis of C12-C13 and the macroaldolization route for C2-C3 bond construction. 
Other methods of connecting the fragments include Suzuki coupling at C11-C12, and aldol 
condensation at C6-C7. 
 
Scheme 1.1 General Retrosynthetic Strategies 
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Since the related work in this thesis will be focused on the C1-C9 polyketide fragment, 
only approaches to that portion of the molecule will be described in more detail. It should be noted, 
however, that the efforts in total synthesis for the epothilones have resulted in a number of 
advances; in particular, the first application of ring-closing metathesis to complex substrates, the 
development of many stereoselective approaches to (Z)-trisubstituted olefins, the finding that the 
Yamaguchi macrolactonization is robust and useful, and the ability to use dimethyldioxirane 
(DMDO) for stereo- and regioselective epoxidation. 
Another point to note, for the purposes of this thesis, is the development of a ring-closing 
metathesis strategy for the formation of a C9-C10 olefin,48 which has been shown to be a positive 
structural modification in a number of analogs such as dehydelone (1.13) and fludelone (1.5) 
(Scheme 1.2).40 It has also been demonstrated that selective hydrogenation of this newly formed 
double bond can be achieved to access the natural products.49 Thus, an efficient synthesis of a C1-
C9 fragment 1.12 would provide versatile access to the natural epothilones as well as a variety of 
important analogs.  
 
Scheme 1.2 Synthesis of Epothilones Using C1-C9 Fragment 1.12 
1.2.4 Synthetic Approaches to the C1-C9 Fragment of the Epothilones 
While the fragment containing the C1-C8 polyketide sector may differ depending on the 
overall synthetic strategy, there are two key challenges in assembling these fragments: the 




 Most reported approaches to the C6-C8 stereotriad utilize a C6-C7 bond-forming reaction 
to set those two stereocenters. This is most often achieved through an aldol addition of an ethyl 
ketone 1.14 with an α-chiral aldehyde 1.16. Other approaches that have been reported include 
crotylation and Danishefsky’s Lewis acid catalyzed diene aldehyde cyclocondensation 
(LACDAC) methodology. 
 
Scheme 1.3 General Anti-Felkin Selective Aldol Approach to the C6-C8 Stereotriad 
 As mentioned, the strategy that has been used the vast majority of the time to construct the 
stereotriad has been an aldol addition. In particular, an anti-Felkin selective aldol between a (Z)-
enolate 1.15 and an α-chiral aldehyde 1.16 is required to achieve the required syn-anti 
stereochemistry of the desired product 1.17 (Scheme 1.3). Precedent for aldol selectivity would 
suggest that the bulky geminal-dimethyl group that is present as part of the R group of ketone 1.14 
would favor the (Z)-enolate, and thus a reaction that proceeds via a chairlike Zimmerman-Traxler 
transition state would lead to formation of the desired C6-C7 syn stereochemistry. 
The selectivity for the stereochemistry of the new C6 and C7 stereocenters relative to the 
existing C8 stereocenter must also be considered. A preference for anti-Felkin selectivity has been 
noted previously in reactions of (Z)-enolates and (Z)-crotylboronates50,51 due to the unfavorable 
syn-pentane interaction of the α-methyl (see 1.18) or gauche-pentane interaction of the larger α-
substituent (see 1.19) from the aldehyde with the enolate methyl substituent that would result with 
Felkin selectivity. Reaction with the opposite face of the aldehyde would minimize steric 
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interactions and result in the lowest energy transition state 1.20, favoring the anti-Felkin product 
with relative anti relationship as the major product (Scheme 1.4). 
 
Scheme 1.4 Potential Transition States for Addition of (Z)-enolates to α-methyl substituted aldehydes 
The described effect has been known to be useful in reliably predicting the major product 
for this type of aldol condensation, however, the selectively is often not very good. This seemed 
to be the case for the substrates used in a number of the early epothilone syntheses, with the 
diastereoselectivities reported ranging from only 1.5:1 to 3:1 in favor of the desired anti-Felkin 
product 1.17 relative to the syn, syn Felkin product (representative examples are presented in 
Scheme 1.5).28,45,52 In all cases, the (Z)-enolate was favored, giving the syn relative stereochemistry 
for the newly formed C6 and C7 stereocenters, as expected. 
 
Scheme 1.5 Selected Aldol Reactions from Epothilone and Beneficial Effect of Acetonide Moiety 
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As additional syntheses were reported, it became clear that the selectivity in this aldol 
reaction was highly dependent on the particular substrates used, with higher selectivities induced 
from longer-range substrate interactions. Schinzer and colleagues found that by utilizing a ketone 
substrate 1.27 containing an acetonide moiety, they could obtain the desired anti-Felkin product in 
70% yield with >19:1 d.r.46 Although various proposals have suggested a chelation effect between 
the lithium cation and the acetonide moiety,53,54 it is unclear which specific transition-state 
interactions are responsible for the high selectivity observed with an acetonide at C3 compared to 
other substrates containing a protected alcohol at C3.  
Table 1.1 Long-Range Effect of Aldehyde Substituents on Aldol Diastereoselectivity 
 
Investigations by the Danishefsky group found that other long-range effects, this time from 
substituents on the aldehyde, are also at play in the diastereoselectivity of these aldol reactions.23,55 
In a screening exercise of various aldehyde substituents, it was found that unsaturation in the 
aldehyde side chain helped improve the diastereoselectivity relative to a substrate without 
unsaturation (Table 1.1, entries 1 and 2). In comparing entries 1 and 3, it can be seen that this effect 
is also dependent on the position of the unsaturation. It has been speculated that this enhancement 
in anti-Felkin selectivity is a result of a non-bonded interaction between the unsaturated moiety 
and either the aldehyde carbonyl55 or lithium cation56,57 that stabilizes the anti-Felkin transition 
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state (Figure 1.5). It should be noted that aldehydes derived from the Roche ester also exhibited 
higher selectivity favoring the anti-Felkin product as expected51 (Table 1.1, entry 4).  
 
Figure 1.5 Proposed Stabilization of Anti-Felkin Transition State 
Thus far, this discussion has focused on how the C6 and C7 stereocenters can be set, but it 
is also important to note the origin of the C8 stereocenter. In the vast majority of cases in which 
an aldol reaction is used to form the C6-C8 stereotriad, the α-chiral aldehyde has either been 
derived from a chiral pool, typically as the Roche ester, or has been set via enolate alkylation 
utilizing chiral auxiliary methodology. While either of these strategies can provide reliable access 
to the desired intermediate, they are not particularly direct syntheses of these chiral α-methyl 
aldehydes because they typically involve a number of oxidation state adjustments, removal of 
chiral auxiliaries, and/or protecting group manipulations. We believe that this is a general problem 
in stereotriad synthesis, and that we might be able to find a more efficient way of accessing the 
third stereocenter of the stereotriad. 
 Although an anti-Felkin selective aldol reaction has been the most widely used approach 
to form the C6-C8 stereotriad, there are a few examples of other approaches in the literature. Panek 
has reported the use of his group’s methodology for the TMSOTf-catalyzed crotylation of α-
silyloxyaldehyde 1.29 with crotylsilane 1.30 to set the C6 and C7 stereocenters in 83% yield and 
15:1 d.r. (Scheme 1.6). Following additional steps, lithium dimethylcuprate addition to enoate 1.32 




Scheme 1.6 Panek’s Crotylation Approach to Epothilone Stereotriad Synthesis 
 Another crotylation approach to the C6-C8 stereotriad was reported by Grieco (Scheme 
1.7).60 In this synthesis, formation of a chiral epoxide via Sharpless epoxidation of 1.34 enabled 
later installation of the chiral C6 methyl through a stereospecific epoxide opening of 1.36 using 
trimethylaluminum to give 1.37. After accessing aldehyde 1.38, Roush asymmetric (E)-crotylation 
was able to install the desired C7 and C8 stereocenters to produce 1.39 as a single diastereomer in 
94% yield. 
 
Scheme 1.7 Grieco’s Crotylation Approach to the C6-C8 Stereotriad 
 Danishefsky’s Lewis acid catalyzed diene aldehyde cyclocondensation (LACDAC) 
approach towards the C6-C8 stereotriad was used in the group’s first reported synthesis of 
epothilones.44,61 This method utilizes chiral α-methyl aldehyde 1.40 derived from the Roche ester 
in a chelation-controlled hetero-Diels-Alder reaction with Danishefsky’s diene 1.39 to access 
dihydropyranone 1.41 as essentially one stereoisomer with all three stereocenters of the stereotriad 
in place (Scheme 1.8). 1,2-Reduction of the carbonyl and a directed Simmons-Smith reaction 
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provided cyclopropane 1.42. Regioselective opening of this strained ring with NIS in methanol, 
followed by deiodination gave 1.44, containing the desired geminal-dimethyl moiety. Subsequent 
steps opened the ring and provided the elaborated C3-C11 linear fragment 1.45. 
 
Scheme 1.8 Danishefsky’s Use of LACDAC Methodology to Construct C6-C8 Stereotriad 
Installation of C3 Stereochemistry 
 The problem of setting the C3 stereocenter has been approached by a variety of strategies. 
Stereoselective aldol condensations have been the most widely used, however the C3 stereocenter 
has also been derived from the chiral pool or established through stereoselective allylation, 
reduction, or epoxidation. 
 Aldol-based approaches to the C3 stereochemistry can be divided into three different 
categories: substrate-based induction, chiral auxiliary, and chiral reagent/catalyst control. For 
substrate-based control (Scheme 1.9), aldol reactions that rely on the stereochemistry of the C6-
C8 stereotriad (with the C5 ketone as it is in the natural product) have been shown to favor the 
desired 3(S) configuration with only approximately 2.5:1 d.r.62,63 Approaches that utilize a C5 
chiral alcohol have been shown to increase selectivity in some cases,60,64 with the highest 
selectivity of 8:1 d.r. reported by Panek using a TiCl4-mediated Mukaiyama aldol reaction between 
1.49 and 1.50.59 Sinha’s alternative strategy to construct the C3-C4 bond instead of the C2-C3 




Scheme 1.9 Examples of Substrate-Based Stereocontrol in Aldol Reactions 
 Chiral auxiliary control has also been used in aldol-based approaches to the formation of 
the C3 stereocenter (Scheme 1.10). Avery’s approach, using the Evans oxazolidinone auxiliary, 
was able to achieve only a modest selectivity of 3:1 for the formation of 1.57.66 However, 
Wessjohann showed that a similar auxiliary could be used in a chromium-mediated, Reformatsky-
type reaction to access 1.59 in 11.5:1 d.r.67  
 
Scheme 1.10 Oxazolidinone Auxiliary Control for the Aldol Approach to C3 Stereochemistry 
De Brabander reported the use of Oppolzer’s sultam auxiliary for a highly 
diastereoselective boron-mediated aldol reaction to set the C3 stereocenter (Scheme 1.11).68 
Another highly selective approach by Schinzer utilized HYTRA acetate 1.6269 as the enolate 




Scheme 1.11 Chiral Auxiliary Control for Aldol Approach of C3 Stereochemistry 
 Stereoinduction of aldol reactions through the use of chiral reagents or catalysts has also 
been reported for generation of the epothilone C3 stereocenter (Scheme 1.12). Using Duthaler’s 
chiral titanium enolate methodology,71 Danishefsky was able to access 1.67 from the C3-C9 
fragment 1.65 in >20:1.72 Another use of chiral reagents, this time with Kiyooka’s chiral borane 
1.70,73 has been reported by both Mulzer and Ley to construct the bond between C3-C4 via an 
enantioselective Mukaiyama aldol reaction, with >90% ee at C3.74,75 An organocatalysis approach 
utilizing D-proline has been used by Avery and co-workers for the aldol reaction of acetone with 
aldehyde 1.72 to form 1.73 in >99% ee.76 
 
Scheme 1.12 Chiral Reagents and Catalysts for Aldol Stereocontrol 
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 Asymmetric allylation has also been frequently reported as an approach to setting the C3 
stereochemistry (Scheme 1.13). Nicolaou’s first synthesis utilized this approach for the 
construction of the bond between C2 and C3. In this case, Brown allylation provided 1.74 in 
excellent enantioselectivity.52 Multzer accomplished the same transformation with the same 
enantioselectivity using Duthaler’s allylation methodology.77 These routes have both been used in 
subsequent total syntheses. Construction of the bond between C3 and C4 has also been achieved 
with high enantioselectivity by Ramachandran through asymmetric prenylation.78 
 
Scheme 1.13 Asymmetric Allylation or Prenylation for Access to C3 Stereocenter 
 Utilizing a chiral pool, Thomas reported an approach in which epothilone C3 
stereochemistry is derived from (R)-pantolactone 1.77 (Scheme 1.14). The C1-C6 fragment can be 
obtained in eight steps by this route.79 Researchers at Schering AG utilized a similar route in their 
synthesis of sagopilone (1.7) and other C6 analogs.43,80 
 
Scheme 1.14 Derivation of C3 via Chiral Pool Synthesis (Pantolactone) 
 Asymmetric reduction of a ketone is an approach that is less frequently used to access the 
C3 stereochemistry. Cases utilizing Noyori’s chiral catalyst for reduction of a β-ketoester have 
shown high levels of selectivity (Scheme 1.15). Danishefsky first reported that a Noyori 
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hydrogenation at a late-stage in his second-generation synthesis was high yielding and proceeded 
in excellent diastereoselectivity (>19:1 d.r.). Their studies towards implementing the reduction 
revealed that the terminal double bond in the substrate was susceptible to competitive reduction, 
but that the C5 ketone was not. In fact, the additional carbonyl group at C5 seemed to be important 
for high levels of selectivity with this substrate, at least in comparison to a substrate containing an 
acetate-protected alcohol at C5.55 Fürstner later reported an application of a highly enantioselective 
Noyori hydrogenation on substrate 1.83 that was closer to the beginning of the route and did not 
have an additional β-carbonyl group.81 
 
Scheme 1.15 Examples of Selective Reduction to Set C3 Stereocenter 
 Recently, Liu has reported a highly enantioselective route to the C1-C6 fragment 1.87 using 
a Jacobsen hydrolytic kinetic resolution of epoxide 1.85 followed by cobalt-catalyzed 
carbonylation of chiral epoxide 1.86 (Scheme 1.16).82  
 
Scheme 1.16 Access to C3 Stereocenter via Epoxidation 
Overall, it should be noted that while a number of the examples that have been described 
are able to install the C3 stereocenter with high levels of selectivity, there are often additional 
oxidation state adjustments and/or protecting group manipulations required in order to either 
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access the desired substrate or to convert the product into a useful form for the next productive 
step (i.e. carbon-carbon bond construction or for selectively accessing a stereocenter). In 
evaluating the construction of the entire C1-C9 fragment, including the incorporation of the C6-
C8 stereotriad, there is still a need for a more efficient overall synthesis. It is our aim to address 
this need through the use of a carbonylation-based approach previously developed by our group. 
1.3 Leighton Group Carbonylation-Based Approach to Polyketide Synthesis 
The Leighton group has had a long standing interest in developing alternative strategies for 
rapid access to polyketide motifs. A strategy utilizing carbonylation was appealing since it could 
provide more direct access to aldehyde functionality without the extra protecting group 
manipulations and oxidation state adjustments necessary in other approaches. A tandem 
silylformylation-allyl(crotyl)silylation approach was developed, first with homoallylic alcohol 
substrates to form skipped polyol arrays83 and then extended to homopropargylic alcohol 
substrates for access to β,β’-dihydroxyketones.84,85 Most recently, this methodology has been 
utilized for the formation of polypropionate stereotriads. 
1.3.1 Tandem Silylformylation-Allyl(Crotyl)silylation and Strain-Release Lewis Acidity 
The Leighton group tandem silylformylation-allylsilylation chemistry was first described 
for homoallylic alcohols (Scheme 1.17). In this approach, the rhodium-catalyzed intramolecular 
alkene silylformylation of diallylsilyl ether 1.88 provides aldehyde 1.89, which undergoes a 
spontaneous and diastereoselective intramolecular aldehyde allylsilylation to form 1.90. Oxidative 
cleavage of the carbon-silicon bond using Tamao oxidation conditions yields skipped triol 1.91 
with the formation of two new stereocenters in 11.5:1 d.r. The mechanism of the silylformylation 
is believed to occur via a similar mechanism as alkene hydrosilylation. After the silicon-hydrogen 
bond undergoes oxidative addition to the rhodium species, the coordination of the alkene and 1,2-
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insertion would provide the same intermediate species as in hydrosilylation. However, the 
migratory insertion of a molecule of carbon monoxide that is coordinated to the metal, followed 
by reductive elimination would give the aldehyde product 1.89 and regenerate the rhodium 
catalyst. 
 
Scheme 1.17 Tandem Alkene Silylformylation-Allylsilylation Reaction and Mechanism 
 The key to this tandem reaction is strain-release Lewis acidity of the silicon that results in 
the spontaneous allylsilylation of aldehyde 1.89. While an acyclic silicon species exhibits 
relatively low Lewis acidity, it has been found that a silane that is incorporated into a four-
membered ring has much higher Lewis acid acidity. Utimoto previously reported this effect in the 
allylation of benzaldehyde using acyclic versus strained allylsilanes (Scheme 1.18).86 Denmark 
has proposed that this property originates from the angle strain at silicon, since the C-Si-C bond 
angle has been compressed from the ideal tetrahedral bond angle of 109.5° to approximately 79°. 
With the coordination of a nucleophile, the silicon can rehybridize to a trigonal bipyramidal 
species, where the compressed angle can be better accommodated by spanning one apical and one 
equatorial position, for which the ideal bond angle is 90°.87 This concept of strain-release Lewis 
acidity also applies to five-membered silacycles such as 1.89 because the approximate C-Si-O 
bond angle is 95°. The coordination of the aldehyde oxygen to the Lewis acidic silicon would 
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relieve the angle strain by allowing the silicon atom to rehybridize as described, and it would also 
activate the aldehyde and allyl group for transfer. 
 
Scheme 1.18 Strain-Release Lewis Acidity 
1.3.2 Tandem Silylformylation-Crotylsilylation of Alkynes  
The silylformylation-crotylsilylation methodology has been further extended to alkyne 
substrates (Scheme 1.19).84,85 Homopropargylic di(cis-crotyl)silyl ethers such as 1.92 undergo the 
same tandem reaction; however, after oxidative cleavage in the Tamao oxidation, the transient enol 
intermediate undergoes tautomerization to provide a ketone-containing 1,5-anti-diol product 1.93. 
A protodesilylative workup is also possible, to give the corresponding alkene product 1.94. 
 
Scheme 1.19 Tandem Alkyne Silylformylation-Crotylsilylation with Oxidative or Protodesilylative Workup 
 The observed diastereoselectivity favoring the 1,5-anti-diol has been attributed to the 
relative rates at which the diastereotopic crotyl groups transfer due to the steric interactions 
associated with the R group (Scheme 1.20). The level of selectivity for these transformations varies 




Scheme 1.20 Stereochemical Model to Explain 1,5-Anti-Diol Bias 
1.3.3 Extension of Methodology to Internal Alkynes for Production of Stereotriads 
Substrates containing internal alkynes are also amenable to the tandem silylformylation-
crotylsilylation methodology (Scheme 1.21).4 The tandem reaction followed by a Tamao oxidation 
resulted in the stereoselective formation of 1.99 in 15:1 d.r. Since the initial product of oxidative 
cleavage is a substituted enol 1.98, diastereoselective tautomerization must occur stereoselectively 
in order to obtain diastereomerically enriched stereotriad product 1.99. 
 
Scheme 1.21 Tandem Silylformylation-Crotylsilylation/Tamao Oxidation for Stereotriad Formation 
The observed anti relationship that is favored for this new methyl-bearing stereocenter 
relative to the vicinal hydroxyl group has been proposed to result from the enol conformation 1.100 
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that results from minimization of steric interactions in a polar, protic environment (Scheme 1.22). 
In this model, the crotyl group can effectively block the back face of the enol, leaving the front 
face open for delivery of a proton. 
 
Scheme 1.22 Rationalized Model for Observed Anti Diastereoselectivity in Tautomerization 
 This methodology has provided a new approach to the synthesis of polypropionate 
stereotriads, which has thus far been utilized in a step-economical synthesis of zincophorin methyl 
ester.7 The application of this particular approach to the C1-C9 fragment of the epothilones will 
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Chapter 2: Improving Selectivity and Efficiency in the Synthesis of the 
C1-C9 Fragment of the Epothilones 
2.1  Introduction: First Generation Synthesis and the “Aprotic” Tamao Oxidation 
As mentioned in the previous chapter, the Leighton group has been interested in applying 
our tandem silylformylation-crotylsilylation/Tamao oxidation methodology towards the 
development of a new highly efficient synthesis of the critical C1-C9 fragment of the epothilones. 
Our group’s first-generation synthesis implemented and further built on this strategy with the 
critical development of alternate Tamao oxidation conditions to allow access to the required 
syn,anti stereochemistry of the C6-C8 stereotriad 2.4.1 Since the previously utilized “standard” 
Tamao oxidation conditions impart anti selectivity in the tautomerization event (as in 2.3), a new 
set of conditions for the Tamao oxidation were developed which promote a syn-selective 
tautomerization following the oxidative cleavage of the C-Si bond (Scheme 2.1). 
 
Scheme 2.1 Tandem Silylformylation-Crotylation with “Standard” vs “Aprotic” Tamao Oxidation 
When considering how the intrinsic selectivity of this tautomerization event could be 
reversed, it was hypothesized that a favorable conformational change in the intermediate enol 
might be caused by the use of “aprotic” conditions that would promote intramolecular hydrogen 
bonding. A conformational model invoking this hydrogen bonding effect seems to predict that 
instead of the back face being blocked by the crotyl group, now the front face would be blocked, 




Scheme 2.2 Rationalized Models for Tautomerization Selectivity under “Standard” vs “Aprotic” Conditions 
Utilizing the in situ generation of dry hydrogen peroxide from a hydroquinone under 
atmospheric pressure of oxygen, as previously reported by Tamao,2 conditions that provided the 
desired syn product 2.4 in 14:1 d.r. at the C6 stereocenter were ultimately found. The development 
of this switch in selectivity, which has enabled access to the desired syn, anti-stereochemistry of 
the stereotriad, was a vital step towards achieving a highly efficient synthesis of the targeted 
epothilone fragment. However, we believed that there were a few problems remaining in the 
overall synthesis of this fragment that could be improved upon. 
 
Scheme 2.3 Leighton Group First-Generation Route to the C1-C9 Fragment 
In the first generation route (Scheme 2.3), synthesis of the key β-hydroxyester intermediate 
2.10 was achieved in 6 steps with 42% overall yield and 87% ee. This was accomplished starting 
with the racemic epoxidation of 2.5, followed by regioselective epoxide opening with an in situ 
formed propynyl aluminate reagent,3 and then TBS deprotection and oxidative cleavage to access 
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aldehyde 2.8. The C3 stereocenter was set via an enantioselective ketene cycloaddition,4 followed 
by alcoholysis of β-lactone 2.9 to provide 2.10. While this strategy provided a reliable route to 
access the desired intermediate, we thought that a more step-economical route to 2.10 could be 
developed, perhaps with enhanced enantioselectivity in setting the C3 stereocenter. 
Addressing the rest of the synthesis, the overall approach of the tandem silylformylation-
crotylsilylation/“aprotic” Tamao oxidation of 2.11 was successful for the rapid construction of the 
C6-C8 stereotriad, with excellent diastereoselectivity for the newly developed “aprotic” Tamao 
oxidation. However, the diastereoselectivity of the crotylation reaction was only 5.5:1 favoring the 
1,5-anti-diol. As mentioned in the previous chapter, in using this tandem silylformylation-
crotylsilylation approach, the level of selectivity in the crotylation is substrate dependent and 
directly influenced by the substituents around the homopropargylic alcohol. Unfortunately, the 
substrate that was required in this synthesis did not exhibit the excellent levels of 
diastereoselectivity that have been found with some of the previously studied substrates. We 
thought that this diastereoselectivity could be improved through the modification of our approach. 
Thus, in our approach to a second-generation synthesis of this fragment, we had two goals: 
first, we hoped to streamline our synthesis for the formation of intermediate 2.10, and second, we 
hoped to improve the diastereoselectivity of the crotylation step. 
2.2 Development of a More Selective and Streamlined Synthesis of Key Intermediate 2.10 
In considering how we could access 2.10 more directly, we thought that we could utilize 
the same regioselective epoxide-opening approach as above to install the alkyne moiety, but 
instead use a chiral epoxide with the ester already in place such as 2.14 (Scheme 2.4). 
Unfortunately, previous attempts for enantioselective epoxidation of the corresponding 
trisubstituted alkene were only able to afford 2.14 in 78% ee at best, via the Shi epoxidation 
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protocol.5 Although this level of enantioselectivity could be acceptable given the more direct route, 
it would also require the “unnatural” enantiomer of the Shi catalyst, which is more difficult to 
access. 
 
Scheme 2.4 Approach to 2.10 via Opening of Chiral Epoxide 
Thinking about other ways to form the chiral epoxide aside from epoxidation of a 
trisubstituted olefin, we considered that 2.14 could be formed from a vicinal-halohydrin, with the 
hydroxyl group stereocenter already established. This strategy ultimately found success with the 
Noyori asymmetric hydrogenation of β-ketoester 2.17 providing vicinal-bromohydrin 2.18 in 
excellent enantioselectivity (>99% ee). After filtration of the ruthenium catalyst, treatment of 2.18 
with sodium carbonate in a mixture of water and ethanol provided chiral epoxide 2.14 in 88% yield 
over two steps. The regioselective epoxide opening gave desired intermediate 2.10 in 60% yield 
(Scheme 2.5).  
 
Scheme 2.5 Optimized route to 2.10 
 During the optimization of this new route, we ran into some difficulties with the epoxide-
forming step. While the base-promoted cyclization of a bromohydrin is a well-precedented method 
for epoxide formation,6–9  we found that our epoxide product 2.14 was susceptible to isomerization, 
forming allylic alcohol 2.19 under these conditions (Scheme 2.6). This was the case even in the 
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absence of a strong base, presumably due to the favorable deprotonation of the β-position (α to 
ester) to form the conjugated ester. We found that weaker bases such as sodium bicarbonate 
resulted in significantly slower conversion to epoxide 2.14, so a balance in the strength of the base 
had to be found to promote fast conversion to 2.14 without significant production of 2.19. 
Ultimately, we found that the conditions given above were able to provide our desired epoxide 
2.14 cleanly in about ten minutes, with 2.19 beginning to form only with extended reaction times. 
 
Scheme 2.6 Proposed Mechanism for Formation of Side Product 2.19 
In comparison to the previous route (Scheme 2.3), our new synthesis of 2.10 is more 
efficient (4 steps vs 6 steps) and provides higher enantioselectivity in the formation of the C3 
stereocenter (>99% ee vs 87% ee). In addition, we were able to demonstrate that this route is 
amenable to multi-gram synthesis, producing 6.5 grams of 2.10 with one pass through the 
sequence. 
2.3 Toward a More Selective Formation of the C6-C8 Stereotriad of the Epothilones 
With an efficient route in place to form 2.10, we also sought to improve the selectivity of 
the crotylation step. As mentioned, the previous intramolecular approach had only provided 5.5:1 
d.r. relative to the existing C3 stereocenter for the crotylation event (Scheme 2.3). Since the 1,5-
anti-diol bias of the crotyl group transfer is substrate-dependent, we thought that the use of an 
external crotylation reagent in an intermolecular approach could provide an opportunity for 




Scheme 2.7 Reagent-Based Approach to Crotylation 
In an intermolecular reagent-based approach, the crotylation of a sterically hindered and 
electronically deactivated aldehyde 2.20 would be required (Scheme 2.7). Fortunately, around that 
time, another member of the Leighton group had found that the reactivity of our diamine-based 
crotylation reagents 2.23 could be significantly enhanced in the presence of catalytic scandium(III) 
triflate.10 With this breakthrough, the highly efficient and enantioselective crotylation of sterically 
hindered and electronically deactivated aldehydes such as 2.22 was now possible (Scheme 2.8). 
With this close precedent, we were optimistic that our new approach could be easily implemented 
to afford a high level of diastereoselectivity for the crotylation. 
 
Scheme 2.8 Precident for Crotylation of Hindered, Electronically Deactivated Aldehydes 
To put our new approach into practice, we began with silylation of our β-hydroxyester 
intermediate 2.10 with diphenylchlorosilane, followed by rhodium-catalyzed silylformylation to 
form aldehyde 2.26. Crotylation of 2.26 with (R,R)-trans-reagent 2.23 afforded 2.27 in 58% overall 
yield for the three steps with >20:1 d.r. (Scheme 2.9). While these steps proceeded smoothly and 
with excellent selectivity induced by the crotylation reagent, attempts to apply the previously 
developed “aprotic” Tamao oxidation conditions to our new substrate 2.27 failed to produce the 




Scheme 2.9 Application of Intermolecular Crotylation Approach 
Applying the “standard” Tamao oxidation conditions provided only very minimal product 
under forcing conditions, with the mass balance consisting of mostly starting material with some 
protodesilylation product 2.29 and other unidentified side products. Additional attempts for the 
oxidative cleavage of substrate 2.27 utilizing conditions that varied the fluoride source and oxidant 
typically resulted in unreacted starting material or 2.29 under some of the harsher conditions 
(Scheme 2.10).  
 
Scheme 2.10 Oxidative Cleavage Attempts on Substrate 2.27 
In considering the source of our difficulties with the oxidative cleavage of 2.27, we 
hypothesized that the presence of the free hydroxyl group at C7 may be impeding the addition of 
the fluoride ion and/or hydrogen peroxide necessary for the Tamao mechanism because of its 
ability to coordinate to silicon. Bearing in mind the strain-release Lewis acidic properties of silicon 
constrained in a five-membered oxasilacycle, it would be expected that the addition of a 
nucleophile to a tetrahedral silicon such as 2.27 would be highly favored to relieve strain through 
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rehydridization into a trigonal bipyramidal species. In the case of the previous substrate 2.2 (which 
has an additional strained ring containing the silicon), this Lewis acidity should promote the 
addition by a fluoride ion, which would activate the substrate for the addition of the hydrogen 
peroxide. In our new substrate 2.27, the intramolecular coordination of the C7 hydroxyl group to 
the silicon may be favored over addition by fluoride, thereby occupying a coordination site on the 
silicon and thus inhibiting the necessary addition by both fluoride and hydrogen peroxide (Figure 
2.1). 
 
Figure 2.1 Comparison of “Aprotic” Tamao Oxidation Substrates 
  The observation that other diphenylsilacycle substrates such as 2.24 have been shown to 
undergo facile oxidative cleavage using the standard (protic) conditions (Scheme 2.11) seems to 
contradict our proposed inhibition effect from intramolecular coordination of the hydroxyl group 
to the silicon. However, since protic conditions would invoke intermolecular hydrogen-bonding 
interactions with the solvent, use of these conditions would be expected to decrease the 
coordination effect described above. Since it was observed that the standard (protic) Tamao 
conditions were not very effective for substrate 2.27, it is likely that there may also be a steric 
effect at play with this substrate due to the geminal-dimethyl moiety close to the silicon. 
 
Scheme 2.11 Precident for the Protic Tamao Oxidation of Related Substrate 2.24 
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At this point, we decided that in order for this new intermolecular crotylation approach to 
work in our synthesis, we would need to find a way to activate our Tamao oxidation substrate 
towards oxidative cleavage. We imagined that the utilization of a silane that had at least one 
fluoride-labile group could allow for its initial displacement by a fluoride group under the Tamao 
oxidation conditions so that the substrate would be more activated for attack by the hydrogen 
peroxide oxidant. 
In our initial efforts to utilize a more “activated” silane, we examined a variety of alkoxy-
substituted chlorosilanes (Scheme 2.12). Unfortunately, we encountered problems using silanes 
such as 2.31a,b due to difficulties in the synthesis or isolation of the silane itself. Furthermore, the 
crotylation product 2.21 from silanes 2.31a,b were unstable and could not be isolated in reasonable 
yields over the three steps from 2.10, presumably due to hydrolysis. 
It became clear that we would need to find a compromise between the stability of the silane 
group and the reactivity of the silane under oxidative cleavage conditions. We imagined that the 
use of a diol-based silane might be able to achieve this desired balance. By linking the two alkoxy 
substituents, the silane could potentially be more activated toward fluoride attack and replacement 
relative to our previous diphenyl substrate 2.27, while at the same time decreasing the hydrolytic 
lability of these alkoxy substituents. 
 
Scheme 2.12 Representative Silanes Explored in the Three-Step Synthesis of 2.21 
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While efficient synthesis and isolation of the diol-based silanes 2.31c,d still proved 
problematic, we were able to isolate 2.31e in a reasonable 68% yield and proceed with the 
silylation-silylformylation-crotylation sequence to provide the corresponding intermediate 2.21e 
in 49% yield over 3 steps from 2.10. With a seeming solution to the stability issues in the synthesis 
of 2.21, we were finally able to test our hypothesis with regards to the “aprotic” Tamao oxidation 
problem. In applying the previously developed “aprotic” Tamao oxidation conditions, we found 
that we could obtain 2.12 in 72% yield and 11:1 d.r. (Scheme 2.13). 
 
Scheme 2.13 Successful “Aprotic” Tamao Reaction of 2.21e for Proof-of-Concept 
This finding established the proof-of-concept, but there was still room to improve upon the 
yield of the isolated crotylation product 2.21. Since the increased steric bulk near the Si-O bond 
could play a significant role in the increased hydrolytic stability of these compounds, we 
hypothesized that increasing the steric bulk even more could further enhance the stabilizing effect 
and increase the yield. Indeed, replacing first one (for silane 2.31f) and then two (for silane 2.31g) 
of the methyl groups on the diol with a tert-butyl group seemed to exhibit a trend for increasing 
yield of the crotylation product (Scheme 2.14). It was also the case that these diol-based silanes 
were synthesized more cleanly and efficiently (93% yield for multiple grams of 2.31g) and were 
easier to handle. The increased steric bulk in silane 2.31g seemed to induce some hindrance in the 




Scheme 2.14 Trend for Increasing Three-Step Yield with Increasing Steric Bulk on the Silane 
 Slight optimization of the “aprotic” Tamao oxidation conditions was achieved through the 
exchange of the previously used 2-methylhydroquinone for 2,3-dimethylhydroquinone. The basis 
for this optimization comes from Tamao’s original report2 for the hydroquinone/dioxygen system. 
This work indicated that the rate of the oxidative cleavage reaction was related to the concentration 
of active oxidant present, and that the rate of hydrogen peroxide generation had a correlation to 
the substitution of the hydroquinone. With increasing substitution from hydroquinone to 2-
methylhydroquinone to 2,3-dimethylhydroquinone, the rate was increased. Thus, when we found 
that the “aprotic” Tamao reaction with 2.21g was stalling as it approached completion, we made 
the exchange to 2,3-dimethylhydroquinone with the hopes that the effect of an increased 
concentration of active oxidant would help drive the reaction to completion. This seemed to be the 
case, with fully optimized conditions providing 2.12 in 71% yield and 9:1 d.r. (Scheme 2.15). 
 
Scheme 2.15 Optimized “Aprotic” Tamao Oxidation of 2.21g 
Overall, our new intermolecular crotylation approach has achieved the rapid generation of 
2.12 from 2.10 in 50% overall yield over four steps with high levels of selectivity in setting the 
three new stereocenters. The final one-pot di-TES-protection and tert-butyl ester hydrolysis of 
2.12 provided the C1-C9 fragment of the epothilones 2.32 in 85% yield (Scheme 2.16). The entire 
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sequence has been performed on a gram scale starting from β-ketoester 2.10, and it is possible that 
even larger scales could ultimately be used to provide efficient access to useful amounts of an 
epothilone or analog. 
 
Scheme 2.16 Final Step to Access C1-C9 Fragment of the Epothilones 
2.4 Summary/Conclusion 
In our new route to the C1-C9 fragment of the epothilones, we have been able to address 
both of the goals that we had at the outset of this project. First, we have developed a more direct 
and streamlined route to the key intermediate 2.10 with excellent selectivity. Our new route is able 
to access 2.10 in just four steps and utilizes an enantioselective Noyori hydrogenation to set the 
C3 stereocenter in >99% enantioselectivity, compared to our previous route which required 6 steps 
and set the C3 stereocenter in 87% ee. From this intermediate 2.10, we can now obtain 2.12 in 
50% over 4 steps. With regards to our second goal of increasing the selectivity of the crotylation 
step, we now achieve >20:1 d.r. for the 1,5-anti-diol (C3/C7) utilizing our crotylation reagent 2.23 
in the presence of catalytic scandium triflate, as compared to the previous 5.5:1 d.r. obtained from 
the intramolecular tandem silylformylation-crotylsilylation approach. 
 
Scheme 2.17 Summary of Our New Route 
Along the way to our new route, we encountered the unexpected setback of the unreactive 
intermediate 2.27. By finding a way to balance the stability of the intermediates and reactivity 
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under the oxidative cleavage conditions through the use of the diol-based silane 2.31g, we have 
been able to circumvent this problem.  
Comparing our synthesis to other reported syntheses of this important polyketide fragment 
of the epothilones, ours has been able to leverage two external sources of chiral induction to set 
the four stereocenters with high levels of selectivity while most other syntheses require three 
external sources of chiral induction for the four stereocenters. Of the reported cases that have been 
able to leverage existing stereochemistry to set other stereocenters, most are through the aldol 
reaction to join (and set) the C6 and C7 stereocenters via anti-Felkin selectivity induced by the 
existing C8 stereocenter. This strategy typically does not provide high levels of selectivity, except 
for very specific substrates which are not generally obtained through the most direct routes. 
Since our new synthesis is direct, scalable, and highly selective, it has potential use towards 
the efficient preparation of an epothilone natural product or analog. As an example of its utility, 
this synthesis has provided a way for us to explore the installation of linker functionality in a C6 
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2.6 Experimental Procedures and Characterization Data 
General Information. All reactions were carried out under an atmosphere of nitrogen in 
flame-dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) was 
carried out on glass-backed silica gel XHL TLC plates (250 μm) from Sorbent Technologies; 
visualization by UV light, p-anisaldehyde stain, phosphomolybdic acid stain, or potassium 
permanganate (KMnO4) stain. Gas chromatographic analyses were performed on a Hewlett-
Packard 6890 Series Gas Chromatograph equipped with a capillary split-splitless inlet and flame 
ionization detector with electronic pneumatics control using a Supelco ß-Dex 325 (30 m x 0.25 
mm) capillary GLC column. 1H NMR spectra were recorded on a Bruker DPX-400 (400 MHz) or 
a Bruker Avance III 500 (500 MHz) spectrometer and are reported in ppm from CDCl3 internal 
standard (7.26 ppm). Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = 
triplet, q = quartet, quin = quintet, sep = septet, m = multiplet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets; coupling constant(s) in Hz; integration). Proton decoupled 13C 
NMR spectra were recorded on a Bruker Avance III 500 (125 MHz) spectrometer and are reported 
in ppm from CDCl3 internal standard (77.16 ppm). Infrared spectra were recorded on a Perkin-
Elmer Spectrum Two (Diamond ATR) IR spectrometer. Optical rotations were recorded on a Jasco 
DIP-1000 digital polarimeter. 
 
To a cooled (0°C) solution of diisopropylamine (4.9 mL, 34.7 mmol) in Et2O (100 mL) 
was added n-BuLi (13.3 mL, 2.5M in hexanes, 33.1 mmol). After 30 minutes, the reaction was 
cooled to -78°C and tert-butyl acetate 2.15 (4.2 mL, 31.6 mmol) was added. After 45 minutes, α-
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bromoisobutyrl bromide 2.16 (4.7 mL, 37.9 mmol) was added. After 90 minutes, the reaction was 
quenched with saturated aqueous NH4Cl (75 mL). The reaction was diluted with Et2O (50 mL) 
and the layers were separated. The aqueous layer was extracted with Et2O (3 x 50 mL), then the 
combined organics were dried over MgSO4, filtered, and concentrated. The crude residue was 
purified via silica gel chromatography (5% EtOAc/hexanes) to provide 2.17 (4.64 g, 55% yield) 
as a clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.77 (s, 2H), 1.88 (s, 6H), 1.46 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 198.3, 166.5, 82.2, 63.9, 44.6, 29.4, 28.0; IR (neat): ʋ (cm-1) 2979, 
2933, 1738, 1713, 1369, 1322, 1257, 1147, 1107, 1056, 956. 
 
A glass liner for a 300 mL capacity Parr bomb apparatus was charged with a solution of 
2.17 (14.13 g, 53.3 mmol) in 1:1 THF:MeOH (100 mL). (R)-BINAP-RuCl2 (1.69g, 2.13 mmol) 
was added then the Parr bomb was assembled and pressurized to 700 psi H2. After 7 hours at room 
temperature the bomb was carefully vented. The solution was concentrated, then the residue 
diluted with pentane and filtered through Celite. The filtrate was concentrated to provide 2.18 as a 
white solid, which was used directly in the next step. For characterization purposes, a pure sample 
of product was obtained via silica gel chromatography (10% EtOAc/hexanes, p-anisaldehyde 
stain). 1H NMR (500 MHz, CDCl3) δ 3.88 (ddd, J = 10.0, 4.7, 2.5 Hz, 1H), 3.15 (d, J = 4.8 Hz, 
1H), 2.72 (dd, J = 16.1, 2.5 Hz, 1H), 2.47 (dd, J = 16.1, 10.0 Hz, 1H), 1.78 (s, 3H), 1.75 (s, 3H), 
1.48 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 172.0, 81.7, 75.7, 70.3, 39.0, 30.5, 30.2, 28.2; IR 
(neat): ʋ (cm-1) 3452, 2978, 2932, 1733, 1708, 1367, 1149, 1110, 851; [α]21D -32.9 (c 1.7, CHCl3). 
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Chiral GC analysis of 2.10 (Supelco β-dex 325, Isothermal 120°C, 1 mL/min) revealed that 2.18 
was produced in >99% enantiomeric excess (ee). 
The concentrated 2.18 was dissolved in EtOH (175 mL) and deionized water (350 mL). 
Na2CO3 (8.46 g, 80.0 mmol) was added and the reaction carefully monitored by TLC (α,β-
unsaturated ester side product 2.19 can form under these conditions with longer reaction times). 
Within 5-10 minutes the starting material was consumed, then reaction was diluted with pentane 
(200 mL). The layers were separated and the aqueous layer was extracted with pentane (3 x 150 
mL). The combined organics were dried over Na2SO4, filtered, and concentrated to provide 2.14 
(8.72 g, 88% yield over 2 steps) as a clear colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.07 (dd, J 
= 6.3, 6.3 Hz, 1H), 2.57 (dd, J = 16.5, 6.3 Hz, 1H), 2.43 (dd, J = 16.5, 6.3 Hz, 1H), 1.47 (s, 9H), 
1.35 (s, 3H), 1.28 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 170.0, 81.1, 59.6, 58.0, 36.1, 28.1, 24.6, 
18.9; IR (neat): ʋ (cm-1) 2979, 2931, 1729, 1368, 1341, 1253, 1154, 1122, 846; LRMS (APCI+) 
calcd C10H19O3 [M+H]+: 187.13, found 187.16; [α]21D +7.3 (c 1.5, CHCl3). 
 
To a cooled (-78°C) solution of propyne (approx. 27 mL, 470 mmol, condensed into a 
cooled (-78°C) graduated cylinder) in Et2O (160 mL) was added n-BuLi (41.2 mL, 2.5 M in 
hexane, 103.0 mmol) dropwise. After 20 minutes, the reaction was warmed to 0°C and AlMe3 
(49.2 mL, 2 M in toluene, 98.3 mmol) was added dropwise. The reaction was warmed to room 
temperature and stirred for 20 minutes. The reaction was again cooled to -78°C and 2.14 (8.72 g, 
46.8 mmol) was added as a solution in Et2O (40 mL), followed by BF3•OEt2 (8.2 mL, 65.5 mmol). 
After 45 minutes, the reaction was slowly quenched with MeOH (50 mL). The mixture was stirred 
for 10 minutes at -78°C then poured into 800 mL of saturated aqueous NaHCO3 solution of pH 10. 
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After stirring for about 45 minutes, the layers were separated and the aqueous layer extracted with 
Et2O (3 x 150 mL). The combined organics were washed with brine, dried over MgSO4, filtered, 
and concentrated. The crude material was purified by silica gel chromatography (10% 
EtOAc/hexanes, p-anisaldehyde stain) to provide 2.10 as a clear, yellow oil (6.30 g, 60% yield).1 
1H NMR (500 MHz, CDCl3) δ 3.77 (ddd, J = 10.4, 4.6, 2.3 Hz, 1H), 2.94 (d, J = 4.6 Hz, 1H), 2.66 
(dd, J = 16.1, 2.4 Hz, 1H), 2.44 (dd, J = 16.1, 10.4 Hz, 1H), 1.83 (s, 3H), 1.50 (s, 9H), 1.23 (s, 
3H), 1.20 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 172.7, 83.4, 81.1, 77.7, 74.5, 38.7, 36.1, 28.1, 
26.2, 24.9, 3.6; IR (neat): ʋ (cm-1) 3480, 2976, 2925, 1718, 1368, 1304, 1153, 1080, 1040, 954; 
[α]20D -43.9 (c 1.6, CHCl3). 
 
A suspension of dried CeCl3 (31.11 g, 126 mmol) in THF (450 mL) was stirred at 40°C 
(oil bath, external temperature) for 2 hours.2,3 The suspension was cooled to -78°C then MeLi (78.8 
mL, 1.6 M in Et2O, 126 mmol) was slowly added. After 2 hours, 5-hydroxy-2,2,5,6,6-
pentamethylheptan-3-one (6.32 g, 31.6 mmol) was added via cannula as a solution in THF (250 
mL). After 1 hour, the reaction was quenched with 10% aqueous acetic acid. After stirring for 
about 1 hour, the reaction was diluted with Et2O (200 mL). The layers were separated and the 
aqueous layer extracted with Et2O (3 x 150 mL). The combined organics were washed with brine, 
dried over MgSO4, filtered, and concentrated. The crude material was purified by silica gel 
chromatography (10% EtOAc/hexanes, PMA stain) to provide one diastereomer of 2.33 as a white 
                                                            
1 Full characterization has been reported: Harrison, T. J.; Rabbatt, P. M. A.; Leighton, J. L. Org. Lett. 2012, 14, 
4890-4893. 
2 Cerium chloride activation: Conlon, D. A.; Kumke, D.; Moeder, C.; Hardiman, M.; Hutson, G.; Sailer, L. Adv. 
Synth. Catal. 2004, 346, 1307-1315. 
3 Precident for diol synthesis: Bartoli, G.; Bosco, M.; Van Beek, J.; Sambri, L. Tet. Lett. 1996, 37, 2293-2296. 
50 
 
solid (5.60 g, 82% yield). 1H NMR (500 MHz, CDCl3) δ 2.64 (s, 2H), 1.63 (s, 2H), 1.32 (s, 6H), 
0.94 (s, 18H); 13C NMR (125 MHz, CDCl3) δ 77.4, 38.9, 37.7, 25.7, 25.1; IR (neat): ʋ (cm-1) 3341, 
2974, 2124, 1636, 1468, 1372, 538. 
 
To a cooled (0°C) solution of dried diol 2.33 (2.49 g, 11.5 mmol) in CH2Cl2 (115 mL) in a 
vigorously dried multi-neck flask was slowly added trichlorosilane (1.28 g, 12.7 mmol) (Caution! 
Evolution of HCl gas), followed by Et3N (4.01 mL, 28.8 mmol) dropwise. After one hour (reaction 
allowed to warm to room temperature), the solvent (and excess trichlorosilane and Et3N) was 
removed in vacuo under inert conditions. Et2O was added and the suspension stirred for thirty 
minutes. The salts were filtered using an inert frit and the filtrate was concentrated to yield 2.31g 
(2.98 g, 93% yield) as a viscous, yellow oil. Analysis by 1H NMR spectroscopy showed 2.31g to 
be a clean 1:1 mixture of diastereomers at silicon. 1H NMR (500 MHz, CDCl3) δ 5.21 (s, 1H), 1.82 
(s, 1H), 1.81 (s, 1H), 1.44 (s, 3H), 1.41 (s, 3H), 0.95 (s, 9H), 0.94 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 82.1, 81.6, 39.3, 39.3, 38.7, 26.8, 25.8, 24.8; IR (neat): ʋ (cm-1) 2957, 2914, 2877, 2225, 
1475, 1396, 1376, 1364, 1150, 1012, 971, 886, 855, 546. 
 
To a cooled (0°C) solution of silane 2.31g (1.05 g, 3.76 mmol) in CH2Cl2 (20 mL) was 
added β-ketoester 2.10 (707 mg, 3.13 mmol) as a solution in CH2Cl2 (10 mL), followed by NEt3 
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(0.65 mL, 4.70 mmol). The reaction was warmed to room temperature over one hour. After five 
hours, 1H NMR analysis was used to determine the conversion of the reaction mixture. Additional 
silane was added if starting material remained. Once complete, the reaction was concentrated and 
the residue filtered through an oven-dried frit with Et2O. The filtrate was concentrated to provide 
intermediate 2.34 as a 1.5:1 mixture of diastereomers, which was used directly in the next step. 
Since this intermediate is difficult to purify due to hydrolytic sensitivity, and both diastereomers 
useful for our purposes, characterization reflects the mixture we obtained. Observed spectra:  1H 
NMR (500 MHz, CDCl3) δ 4.52 (s, 1H), 4.19 (d, J = 9.2 Hz, 1H), 2.82 (d, J = 15.9 Hz, 1H), 2.46 
(dd, J = 15.2, 10.0 Hz, 1H), 1.80 (s, 3H), 1.75 (s, 2H), 1.51 (s, 9H), 1.37 (s, 3H), 1.36 (s, 3H), 1.25 
(s, 3H), 1.15 (s, 3H), 0.95 (s, 18H). 13C NMR (125 MHz, CDCl3) δ 171.0, 171.0, 84.5, 84.5, 80.4, 
80.3, 79.9, 79.7, 79.5, 79.2, 76.1, 75.9, 40.3, 40.0, 39.1, 39.0, 38.9, 38.9, 38.3, 38.2, 36.1, 28.2, 
28.2, 27.0, 27.0, 27.0, 26.9, 25.7, 25.6, 24.8, 24.7, 24.7, 23.5, 23.1, 3.5, 3.4; LRMS (FAB+) calcd 
C26H49O5Si [M+H]+: 469.33, found 469.35. 
 
A glass liner for a Parr bomb was charged with the crude 2.34 (from previous reaction) as 
a solution in CH2Cl2 (7.8 mL). The bomb was assembled and pressurized with CO to 
approximately 500 psi and then vented. This procedure was repeated two more times, then the 
bomb was pressurized again to 500 psi and stirred for about fifteen minutes. The bomb was 
carefully vented and opened, then Rh(acac)(CO)2 (0.125 mmol, 32 mg) was added. The bomb was 
reassembled and pressurized to 500 psi with CO then stirred at ambient temperature. After 16 
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hours, the bomb was carefully vented and opened. 1H NMR analysis indicated complete 
consumption of starting material and clean formation of product 2.35 as a 1.6:1 mixture of 
diastereomers. This reaction solution was used directly in the following crotylation reaction. 
Observed spectra of the diastereomeric mixture were as follows: 1H NMR (500 MHz, CDCl3) δ 
10.09 (s, 1H), 10.05 (s, 1H), 4.17 (dd, J = 10.4, 3.2 Hz, 1H), 4.09 (dd, J = 9.9, 2.7 Hz, 1H), 2.53 – 
2.41 (m, 2H), 2.42 – 2.29 (m, 2H), 2.16 (m, 1H), 2.00 (s, 3H), 1.99 (s, 2H), 1.83 (m, 3H), 1.50 (m, 
2H), 1.48 (m, 16H), 1.45 (s, 3H), 1.42 (s, 3H), 1.35 – 1.26 (m, 16H), 1.11 (s, 3H), 0.98 (s, 7H), 
0.99 – 0.92 (m, 37H). 13C NMR (125 MHz, CDCl3) δ 195.5, 195.3, 171.2, 170.7, 165.2, 163.2, 
148.1, 147.4, 81.2, 81.1, 80.7, 80.6, 80.5, 80.1, 80.0, 78.2, 48.0, 47.2, 41.6, 39.6, 39.5, 39.3, 39.2, 
38.4, 37.9, 28.1, 27.9, 27.7, 26.9, 26.8, 26.2, 24.9, 24.9, 24.1, 23.7, 22.3, 20.1, 14.1, 11.9, 11.9. 
LRMS (FAB+) calcd C27H49O6Si [M+H]+: 497.32, found 497.35. 
 
To a solution of the reaction mixture from aldehyde 2.35 formation in CH2Cl2 (31 mL) was 
added (R, R)-trans-crotylsilane reagent 2.23 (2.32 g, 4.07 mmol) and Sc(OTf)3 (154 mg, 0.313 
mmol).4 After 20 hours at room temperature, the reaction was cooled to 0°C and 
tetrabutylammonium fluoride (TBAF) trihydrate (0.99 g, 3.13 mmol) was added portion-wise over 
20 minutes. After about 3 hours, the reaction was concentrated and the residue purified via silica 
                                                            
4 Kim, H.; Ho, S.; Leighton, J. L.; J. Am. Chem. Soc. 2011, 133, 6517-6520. 
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gel chromatography (10% EtOAc/hexanes) to afford 2.21g (1.21 g, 70% over 3 steps) as a viscous 
yellow oil. 2.21g was a 1.5:1 mixture of diastereomers at silicon, with the crotylation providing 
>20:1 d.r for the installation of C7/C8 relative to the existing stereocenter at C3.  1H NMR (500 
MHz, CDCl3) δ 5.81 – 5.62 (m, 2H), 4.95 (s, 2H), 4.93 – 4.90 (m, 2H), 4.18 – 4.05 (m, 4H), 2.92 
(s, 2H), 2.56 – 2.43 (m, 4H), 2.28 (dd, J = 10.5, 3.6 Hz, 1H), 2.25 (dd, J = 10.5, 3.8 Hz, 1H), 1.86 
(s, 3H), 1.85 (s, 3H), 1.79 (s, 2H), 1.78 (s, 1H), 1.44 (s, 9H), 1.44 (s, 12H), 1.42 (s, 3H), 1.41 (s, 
6H), 1.27 (s, 4H), 1.25 (s, 2H), 1.22 (s, 2H), 1.19 (s, 3H), 1.17 (d, J = 4.9 Hz, 3H), 1.16 (d, J = 4.9 
Hz, 3H), 1.00 – 0.92 (m, 36H); 13C NMR (125 MHz, CDCl3) δ 173.5, 173.4, 158.4, 158.1, 139.2, 
139.1, 134.2, 134.1, 114.8, 114.8, 83.4, 83.2, 80.8, 80.7, 80.5, 80.2, 80.1, 79.9, 73.8, 73.8, 41.7, 
41.6, 41.6, 41.4, 40.0, 39.9, 39.6, 39.5, 38.5, 38.4, 38.1, 37.8, 28.6, 28.4, 28.3, 28.3, 28.1, 27.8, 
26.5, 26.4, 25.3, 25.2, 25.2, 24.5, 24.4, 18.4, 18.3, 17.8, 17.6; IR (neat): ʋ (cm-1) 3497, 2972, 2929, 
2875, 1713, 1472, 1452, 1367, 1151, 1026; LRMS (FAB+) calcd C31H57O6Si [M+H]+: 553.38, 
found 553.40. 
 
To a solution of 2,3-dimethylhydroquinone (694 mg, 5.03 mmol), quinuclidine 
hydrochloride (801 mg, 5.43 mmol), and silver fluoride (816 mg, 6.43 mmol) in benzonitrile (10 
mL) was added 2.21g (1.11 g, 2.01 mmol) as a solution in benzonitrile (10 mL). The solution was 
purged with O2 then the reaction was heated to 60°C (oil bath, external temperature) and stirred 
under a balloon of O2. After 16 hours, the reaction was cooled to room temperature and diluted 
with CHCl3 (20 mL). The solution was filtered through Celite, then washed with distilled water. 
The aqueous layer was extracted with CHCl3 (3 x 20 mL). The combined organics were washed 
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with brine, dried over MgSO4, filtered, and concentrated. Most of the benzonitrile was removed 
by distillation under reduced pressure. The residue was purified via silica gel chromatography 
(stepwise: 5% EtOAc/hexanes to 10% EtOAc/hexanes to 15% EtOAc/hexanes) to provide 2.12 
(470 mg, 71%) as a red oil with 9:1 diastereomeric ratio (d.r.) with respect to the newly formed 
stereocenter at C6. 1H NMR (400 MHz, CDCl3) δ 5.90 (ddd, J = 17.4, 10.4, 7.6 Hz, 1H), 5.15 – 
5.04 (m, 2H), 4.20 (ddd, J = 10.2, 3.2, 2.6 Hz, 1H), 3.53 (ddd, J = 8.0, 2.2, 2.0 Hz, 1H), 3.36 (d, J 
= 3.4 Hz, 1H), 3.25 (qd, J = 6.9, 2.4 Hz, 1H), 3.16 (d, J = 2.0 Hz, 1H), 2.39 (dd, J = 16.3, 2.5 Hz, 
1H), 2.34 – 2.25 (m, 2H), 1.47 (s, 9H), 1.20 (s, 3H), 1.13 (s, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.00 (d, 
J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 221.5, 172.7, 141.3, 115.0, 81.8, 74.7, 72.7, 52.1, 
41.8, 40.8, 37.5, 28.3, 21.5, 19.1, 16.8, 10.8; [α]21D -50.4 (c 1.15, CHCl3). Stereochemical Proof: 
1H and 13C NMR spectra and sign of optical rotation for 2.12 match the previously published 
compound, for which stereochemical proof of correct epothilone stereochemistry was established.1 
 
To a cooled (-78°C) solution of 2.12 (170 mg, 0.517 mmol) in CH2Cl2 (5.2 mL) was added 
2,6-lutidine (0.48 mL, 4.14 mmol). TESOTf (0.35 mL, 1.55 mmol) was then added dropwise. After 
30 minutes, a second portion of TESOTf (0.35mL, 1.55 mmol) was added and the cold bath was 
removed, allowing the reaction to warm to ambient temperature. After 3 hours, the reaction was 
cooled to 0°C and quenched with saturated aqueous NaHCO3. After stirring for thirty minutes, the 
layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 5 mL). The combined 
organics were concentrated then the residue was diluted with Et2O. This was washed quickly and 
carefully with 0.25 M aqueous HCl (TLC monitoring of ether layer is necessary to separate layers 
before silyl group deprotection). The organic layer was washed with brine, dried over Na2SO4, 
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filtered, and concentrated. Purification via silica gel chromatography (15% EtOAc/hexanes) 
provided 2.32 (220 mg, 85% yield) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ 10.02 (bs, 
1H), 5.92 (ddd, J = 17.9, 10.5, 8.0 Hz, 1H), 5.06 (dd, J = 10.6, 1.4 Hz, 1H), 5.00 (dd, J = 17.5, 2.8 
Hz, 1H), 4.39 (dd, J = 7.1, 3.1 Hz, 1H), 3.88 (dd, J = 7.9, 1.8 Hz, 1H), 3.03 (dq, J = 14.2, 7.0 Hz, 
1H), 2.51 (dd, J = 16.4, 3.1 Hz, 1H), 2.33 (dd, J = 16.4, 7.1 Hz, 1H), 2.10 – 2.02 (m, 1H), 1.21 (s, 
3H), 1.11 (s, 3H), 1.06 (d, J = 5.5 Hz, 3H), 1.04 (d, J = 5.5 Hz, 3H), 1.01 – 0.92 (m, 18H), 0.69 – 
0.61 (m, 12H); 13C NMR (125 MHz, CDCl3) δ 218.6, 175.7, 139.8, 115.5, 77.2, 73.6, 53.3, 46.3, 
43.0, 39.4, 23.9, 19.2, 18.9, 15.2, 7.1, 6.9, 5.5, 5.1; IR (neat): ʋ (cm-1) 2955, 2913, 2877, 1710, 
1458, 1416, 1100, 1004, 988, 733; LRMS (APCI+) calcd C14H23O3 [M+Na]+: 523.33, found 



















































2.8 GC Traces 
Chiral GC analysis of 2.10 (product after opening of epoxide 2.14) revealed 
that 2.18 was produced in >99% enantiomeric excess (ee). 
 









Chapter 3: Application of Our Fragment Synthesis for a 
C6 Linker Analog of Epothilone B 
 
3.1 Introduction: Aims and Rationale for C6 Methyl Conjugation 
Despite potent antiproliferative and cytotoxic activity against a variety of cancer cell lines, 
epothilones have not yet achieved their full potential as chemotherapic agents due to their intrinsic 
lack of selectivity in acting against malignant versus normal cells. Since these compounds act by 
binding to tubulin to disrupt microtubule dynamics and thus arrest cells during cell division, the 
increased rate of proliferation of many cancer cells can impart enough selectivity for some clinical 
value; however, simultaneous action against healthy tissues often leads to significant side effects. 
The most problematic of these adverse effects include hematological toxicity, peripheral sensory 
neuropathy, and a variety of gastrointestinal complications.1 
A strategy that could reduce these side effects is the targeted delivery of a drug molecule 
via conjugation to a tumor-targeting moiety.2 Antibody-drug conjugates (ADCs) have become a 
popular way to approach targeting efforts, with many currently in clinical trials.3,4 Two ADCs have 
recently been approved by the FDA, both for cancer chemotherapy.5 Other groups such as receptor-
binding proteins, folates, and nanoparticles have also been used for this type of targeting 
strategy.6,7 The development of bioorthogonal reactions has provided a useful way to selectively 
assemble these systems once the components (targeting moiety and drug molecule) are obtained, 
without disturbing the other functionality that is present.8 
In approaching the conjugation of a drug molecule, the two main points to be considered 
are the location of the linker and how it will be installed. Addressing the first point, the most 
important concern is that the linker must be tolerated such that there is not significant loss of 
binding affinity or potency. In order to do that, the extension must be pointing away from the 
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binding pocket of its receptor. Since it is impossible to know whether an unexplored linker position 
will be useful without making the compounds and testing it, the second concern of how the linker 
will be installed is very important as well. If a promising linker position is difficult to access, it 
may not be pursued. 
Considering ways to install a covalent linker to a drug molecule in the non-aromatic 
polyketide class, the simplest approach is often through the acylation of a hydroxyl group present 
in the parent molecule. Concerns for potential ester hydrolysis in vivo make this type of covalent 
attachment less desirable to implement than an alternative approach that would ensure that the 
linker could not be cleaved unintentionally. In addition, the modification of an alcohol moiety may 
disrupt important hydrogen bonding interactions with the binding site. In the case of the 
epothilones, both of the hydroxyl groups (at C3 and C7) appear to be important for binding due to 
hydrogen-bonding interactions with β-tubulin. The high resolution crystal structure of Epo A 
bound to tubulin that has been reported shows that the C3 OH has a hydrogen-bonding interaction 
with the side chain nitrogen of the Gln281 residue and the C7 OH has a hydrogen-bonding 
interaction with the side chain oxygen of the Asp226 residue.9 
 
Figure 3.1 Examples of Reported Epothilone Linker Strategies 
Other ways of attaching a molecule to a linker require more direct structural modification, 
potentially through the installation of a new functional group or the modification of an existing 
group in the parent compound. Reports of epothilone analog exploration towards bioconjugation, 
whether for targeted delivery or for labeling studies, have focused primarily on modification of 
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either the heterocyclic side chain, such as in 3.1,6 or the epoxide region, such as in 3.2,10 3.3,11,12 
and 3.413 (Figure 3.1). The only epothilone conjugate that has had reported success and advanced 
to clinical trials is epofolate, which is comprised of an aziridine-based analog 3.2 linked to folic 
acid.6 However, these trials have since been terminated due to instability issues. 
Although there have been some reports of C-H activation methods used for 
conjugation,14,15 the modification of unactivated C-H bonds has been largely unexplored. A 
strategy that would require a less obtrusive structural change to the parent molecule would be the 
linear extension of one of the existing methyl groups within the molecule. This type of 
modification would replace the methyl with a longer chain that has functionality at the end to allow 
covalent coupling of the completed drug molecule to a longer linker. Modification to a solvent-
exposed methyl group should, in principle, have minimal steric and electronic perturbation of the 
conformation relative to the parent compound such that coordination to the binding site would be 
as efficient and thus the compound should maintain its activity. To our knowledge, there are only 
two reported examples of this approach being used. The first example is a C16 methyl modification 
explored in Schreiber’s discodermolide studies, which ultimately did not prove useful due to lack 
of activity.16 The second example is a C6 modification of a methyl substituent into an allyl group 
in epothilones B and D for the purpose of tritium radiolabeling studies, as investigated by 
researchers at Schering AG.17 This modification and the subsequent labelled products maintained 
activity, but only represent a two-carbon extension of the methyl group so does not demonstrate 
whether conjugation with a longer linker is possible. 
Our group has recently become interested in methyl modification as a general conjugation 
strategy to explore polyketide linker analogs. Since such a deep-seated modification requires a full 
synthesis for each analog, we are most interested in pursuing this strategy with molecules for which 
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we have developed highly efficient syntheses that would allow rapid access to analogs. Exploration 
towards methyl conjugation of dictyostatin is currently under way, utilizing our group’s recently 
reported synthesis.18 
Upon completion of our highly stereoselective synthesis of the C1-C9 fragment of the 
epothilones, we became interested in applying it towards the investigation of C6 methyl 
conjugation analogs 3.6 of the natural product epothilone B 3.5. Since the overall synthesis of the 
epothilones is modular and our synthesis of the C1-C9 fragment is highly efficient, the installation 
and study of products containing various linker chains at the C6 position within a reasonable 
timeframe is feasible, given a stockpile of the other two epothilone components 3.7 and 3.8. 
Although we decided to use the natural product epothilone B for this study, a fragment 3.9 could 
easily be used in the future towards the synthesis of C6 linker analogs for many of the other 
synthetic epothilones by varying the other components 3.7 and 3.8. 
 
Scheme 3.1 Proposed C6 Linker Analog of Epothilone B and Disconnection Strategy 
The rationale behind our interest in targeting modification of the C6 methyl is twofold. 
First, although the stereochemistry of the C6-C8 stereotriad cannot be modified, there has been 
precedent for the extension of the C6 methyl to a longer group by the researchers at Schering AG, 
as mentioned previously.  The SAR data they reported for the C6 ethyl analog of epothilone B 3.11 
has shown at least a four-fold enhancement in potency relative to the parent compound across a 
variety of cancer cell lines, while more limited data for the related C6 allyl (3.12) and propyl (3.13) 
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analogs have indicated only slightly reduced activity in multi-drug resistant cell lines relative to 
epothilone B 3.5.17 These studies are related to the more familiar example of C6 modification 
represented by the exchange of this methyl for an allyl group in sagopilone 3.10, a compound 
currently in clinical trials.19,20 
 
Figure 3.2 Precedent for Tolerated C6 Methyl Extension 
Second, the high resolution crystal structure of αβ-tubulin in complex with epothilone A 
that was just reported in 2013 indicates that the C6 methyl is solvent exposed (Figure 3.3).9 The 
choice of a solvent-exposed position is vital if we want to be able to extend a much longer chain 
from our linker without altering the binding affinity. Since this information was consistent with 
the previously described precedent of C6 methyl extension, it provided more motivation for 
targeting conjugation of the C6 methyl. 
 
Figure 3.3 Crystal Structure of αβ-Tubulin in Complex with Epothilone A (C6 Indicated with Arrow) 
With our new route in place for access to the C1-C9 fragment and some precedent for our 
intended C6 modification, we were hopeful that we would be able to obtain our desired analog. If 
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biological testing shows that our analogs can maintain potency, then applications utilizing a linker 
at this position can be further pursued.  
3.2 Application of Our C1-C9 Fragment Synthesis Towards a C6 Epothilone Linker Analog 
In applying our previously described synthesis to access C6 methyl derivatives of the C1-
C9 epothilone fragment, the linker group could be installed by utilizing the corresponding terminal 
alkyne 3.15 in place of propyne for the epoxide opening step (Scheme 3.2). The required 
stereochemistry for this C6 position would be set using the “aprotic” Tamao oxidation conditions. 
Since these syn-selective conditions had not been applied for use outside of the previously 
described work towards the epothilone fragment in chapter 2, we did not know if the methyl group 
substitution would affect the selectivity of this reaction. 
 
Scheme 3.2 Proposed Adaptation of Previous Synthesis for C6 Analogs 
 In choosing a linker group to install, we decided to target a carbon chain with a terminal 
chloride, which could later be converted to an azide. Since we were not confident that an azide 
would be tolerated under all of the conditions necessary to access an epothilone B analog, we 
planned to install it as one of the final steps. With an azide at the end of our linker, we should be 
able to evaluate the potential use of either a click reaction21,22 or traceless Staudinger ligation23 for 
covalent attachment to a longer tether. 
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Putting this approach into practice, we found that the epoxide-opening step proceeded 
smoothly using chloroalkyne 3.19 to afford 3.20 in 84% yield. Silylation with chlorosilane 3.21 
followed by rhodium-catalyzed silylformylation provided 3.23, as expected. However, crotylation 
with reagent 3.24 exhibited decreased rate and selectivity, providing a 3.5:1 mixture of desired 
1,5-anti-diols with 1,5-syn-diol. After removing the undesired 1,5-syn-diol product by 
chromatography, 3.25 was isolated in 37% yield over 3 steps from 3.20 in a 2:1 mixture of 
diastereomers at silicon.  
 
Scheme 3.3 Installation of C6 Linker via Alkyne 3.19 
Although the crotylation selectivity has been eroded, we were still able to access the 
required “aprotic” Tamao oxidation substrate 3.25 via this route, so we could continue with our 
analog exploration. If our C6 methyl analogs prove useful, this route can be revisited to examine 
the use of silanes other than 3.21. In particular, since the increased steric hindrance from the 
substitution at the C6 methyl may help stabilize the intermediates relative to original system, it 
may be possible to reduce the bulkiness of silane 3.21 to a silane with methyl substituents in place 




Scheme 3.4 “Aprotic” Tamao Oxidation to Access to 3.27 
Moving forward to test our new substrates 3.25 in the “aprotic” Tamao oxidation, we 
happily found that the selectivity for this reaction had increased, providing access to 3.27 in 75% 
yield and >18:1 d.r (Scheme 3.4). With the C1-C9 analog fragment in hand, we were prepared to 
move forward with the synthesis of our targeted C6 linker analog of epothilone B. 
3.3 Use of Our Fragment Analog to Access to a C6 Linker Analog of Epothilone B 
 
Scheme 3.5 Route Used to Access C6 Linker Analog of Epothilone B 
In the synthesis of our C6 linker analog (Scheme 3.5), we utilized a previously described 
route reported by the Danishefsky group, which had been demonstrated to provide access to 
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epothilone B via our C1-C9 fragment.24–27 Following the double TES protection and the tert-butyl 
ester cleavage of 3.27, fragment 3.28 was used directly for the esterification of fragment 3.8. Ring-
closing metathesis of 3.29 using Grubbs second generation catalyst provided 3.30 in 66% yield. 
The thiazole-containing side chain was installed via Wittig olefination of 3.30 using the 
phosphonium ylide derived from 3.7 to complete the construction of the epothilone skeleton. Silyl 
group deprotection followed by selective diimide reduction of the C9-C10 disubstituted olefin 
provided 3.33. We chose this point to install the azide, forming 3.34 in excellent yield. This was 
followed by diastereoselective epoxidation using dimethyldioxirane to access our desired C6 linker 
analog of epothilone B 3.35. 
 After obtaining our azide-containing analog 3.35, we were able to access both a triazole 
derivative 3.36 and an acetamide derivative 3.37, through a strain-released click reaction21 and 
traceless Staudinger ligation,23 respectively (Scheme 3.6). All three of these compounds were 
submitted for biological testing against a variety of cancer cell lines. 
 
Scheme 3.6 Conversion of Azide 3.35 into Triazole and Acetamide Derivatives 
Table 3.1 shows the preliminary results that our collaborators have determined thus far for 
compounds 3.35, 3.36, and 3.37, along with some reference compounds, across four different cell 
lines. From this data, it appears that our linker analogs have not lost activity through extension of 
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the methyl group or through incorporation of the amide or triazole functionalities at the end of the 
butyl linker. Although repeat experiments are still underway for future publication, the consistency 
of potency across different cancer cell lines indicates that the qualitative result (that the analogs 
maintain potency compared to the parent compounds) is reliable, and thus our C6 linker strategy 
is viable and can be further developed. 









Taxol (6) (<0.13) 2.6 1.9 
Ixabepilone 4 (2) 2.5 3.3 
Epo A  7 (7) 5.5 6 
3.35 (2.1) (<0.65) (0.4) (1) 
3.36 2.3 (<0.65) 0.5 7 
3.37 (1) (0.65) (0.6) (2.2) 
Notes: These are preliminary results, with further testing underway (Dan Sackett, NIH) 
           Numbers in ( ) represent one data point and numbers without ( ) represent two data points 
 
3.4 Conclusion and Outlook 
Through application of our previously described synthesis of the C1-C9 fragment of the 
epothilones, we have been able to install a linker at the C6 position through a methyl modification 
strategy. Although we have utilized the natural product epothilone B as a basis to assess the 
viability of this linker position and strategy, our modified C1-C9 fragment would not limited to 
this use. Since the vast majority of natural and synthetic epothilones do not contain any structural 
modification within the C1-C9 portions of the molecule,28,29 our linker-equipped C1-C9 fragment 
could be utilized in the synthesis of linker analogs of a variety of other known and promising 
epothilones.  In fact, the route that we have used to access the final product (Scheme 3.6) proceeds 
through intermediates which are themselves C6 analogs of known potent compounds, such as 
3.3226 and 3.33 (epothilone D). 
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Given our positive results in the biological testing of our compounds, we believe that we 
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3.6 Experimental Procedures and Characterization Data 
General Information. All reactions were carried out under an atmosphere of nitrogen in 
flame-dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) was 
carried out on glass-backed silica gel XHL TLC plates (250 μm) from Sorbent Technologies; 
visualization by UV light, p-anisaldehyde stain, phosphomolybdic acid stain, or potassium 
permanganate (KMnO4) stain. Gas chromatographic analyses were performed on a Hewlett-
Packard 6890 Series Gas Chromatograph equipped with a capillary split-splitless inlet and flame 
ionization detector with electronic pneumatics control using a Supelco ß-Dex 325 (30 m x 0.25 
mm) capillary GLC column. 1H NMR spectra were recorded on a Bruker DPX-400 (400 MHz) or 
a Bruker Avance III 500 (500 MHz) spectrometer and are reported in ppm from CDCl3 internal 
standard (7.26 ppm). Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = 
triplet, q = quartet, quin = quintet, sep = septet, m = multiplet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets; coupling constant(s) in Hz; integration). Proton decoupled 13C 
NMR spectra were recorded on a Bruker Avance III 500 (125 MHz) spectrometer and are reported 
in ppm from CDCl3 internal standard (77.16 ppm). Infrared spectra were recorded on a Perkin-
Elmer Spectrum Two (Diamond ATR) IR spectrometer. Optical rotations were recorded on a Jasco 
DIP-1000 digital polarimeter. 
 
To a cooled (0°C) solution of 3.19 (2.3 mL, 19.1 mmol) in Et2O (60 mL) was added n-
BuLi (7.6 mL, 2.5 M in hexane, 19.1 mmol) dropwise. After 5 minutes, AlMe3 (9.1 mL, 2 M in 
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toluene, 18.3 mmol) was added dropwise. The reaction was warmed to room temperature and 
stirred for 15 minutes. The reaction was then cooled to -78°C and 3.14 (1.62 g, 8.70 mmol) was 
added as a solution in Et2O (15 mL), followed by BF3•OEt2 (2.2 mL, 17.4 mmol). After 45 minutes, 
the reaction was slowly quenched with MeOH (20 mL). The mixture was stirred for 10 minutes 
then poured into 30 mL of saturated aqueous NaHCO3 solution of pH 10. After stirring for about 
45 minutes, the layers were separated and the aqueous layer extracted with Et2O (3 x 60 mL). The 
combined organics were washed with brine, dried over MgSO4, filtered, and concentrated. The 
crude material was purified by silica gel chromatography (8% EtOAc/hexanes, p-anisaldehyde 
stain) to provide 3.20 as a clear, yellow oil (2.20 g, 84% yield). 1H NMR (500 MHz, CDCl3) δ 
3.75 (ddd, J = 10.4, 4.5, 2.3 Hz, 1H), 3.56 (t, J = 6.6 Hz, 2H), 2.91 (d, J = 4.5 Hz, 1H), 2.62 (dd, 
J = 16.0, 2.4 Hz, 1H), 2.39 (dd, J = 16.0, 10.4 Hz, 1H), 2.21 (t, J = 7.0 Hz, 2H), 1.92 – 1.82 (m, 
2H), 1.69 – 1.60 (m, 2H), 1.47 (s, 9H), 1.20 (s, 3H), 1.18 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
172.8, 85.4, 81.6, 81.3, 74.6, 44.7, 38.8, 36.3, 31.8, 28.3, 26.4, 26.3, 24.9, 18.2; IR (film): 3494, 
2974, 2934, 2868, 1712, 1455, 1392, 1367, 1302, 1254, 1151, 1079, 1041, 950, 762, 651 cm-1; 
LRMS (FAB+) calcd C16H28ClO3 [M+H]+: 303.16, found 303.29; [α]20D -28.7 (c 1.20, CHCl3). 
 
To a cooled (0°C) solution of silane 3.21 (817 mg, 2.93 mmol) in CH2Cl2 (28 mL) was 
added β-ketoester 3.20 (845 mg, 2.79 mmol) as a solution in CH2Cl2 (10 mL), followed by NEt3 
(0.58 mL, 4.19 mmol). The reaction was warmed to room temperature after 30 minutes. 1H NMR 
analysis was used to determine the conversion of the reaction mixture. Additional silane was added 
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if starting material remained. Once complete, the reaction was concentrated and the residue filtered 
with Et2O through an oven-dried frit. The filtrate was concentrated to provide intermediate 3.22 as 
a 1:1 mixture of diastereomers, which was used directly in the next step. Since this intermediate is 
difficult to purify due to hydrolytic sensitivity, and both diastereomers useful for our purposes, 
characterization reflects the mixture we obtained. Observed spectra: 1H NMR (500 MHz, CDCl3) 
δ 4.47 (m, 2H), 4.13 (m, 2H), 3.55 (t, J = 6.6 Hz, 4H), 2.76 (m, 2H), 2.44 (m, 2H), 2.19 (t, J = 6.9 
Hz, 4H), 1.92 – 1.81 (m, 4H), 1.69 (m, 4H), 1.67 – 1.57 (m, 4H), 1.47 (m, 18H), 1.37 – 1.28 (m, 
12H), 1.21 (m, 6H), 1.12 (m, 6H), 0.94 – 0.87 (m, 36H); 13C NMR (125 MHz, CDCl3) δ 171.2, 
171.2, 86.3, 86.2, 81.2, 81.1, 80.7, 80.6, 80.0, 79.8, 79.6, 79.3, 77.4, 76.1, 75.9, 44.8, 40.5, 40.1, 
39.2, 39.2, 39.1, 39.0, 38.3, 38.2, 36.2, 36.1, 31.7, 31.6, 28.4, 28.3, 27.3, 27.1, 27.1, 26.2, 25.8, 
25.7, 24.9, 24.9, 24.9, 23.7, 23.4, 18.2, 18.2. 
 
A glass liner for a Parr bomb was charged with the crude 3.22 (from previous reaction) as 
a solution in CH2Cl2 (5.6 mL). The bomb was assembled and pressurized with CO to 
approximately 500 psi and then vented. This procedure was repeated two more times, then the 
bomb was pressurized again to 500 psi and stirred for about fifteen minutes. The bomb was 
carefully vented and opened, then Rh(acac)(CO)2 (0.223 mmol, 58 mg) was added. The bomb was 
reassembled and pressurized to 500 psi with CO then stirred at ambient temperature. After 24 
hours, the bomb was carefully vented and opened. 1H NMR analysis indicated complete 
consumption of starting material and clean formation of product 3.23 as a 1.2:1 mixture of 
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diastereomers. This reaction solution was used directly in the following crotylation reaction. 
Observed spectra of the diastereomeric mixture were as follows: 1H NMR (500 MHz, CDCl3) δ 
10.09 (s, 1H), 10.04 (s, 1H), 4.16 (dd, J = 10.3, 3.4 Hz, 1H), 4.10 (dd, J = 10.0, 2.8 Hz, 1H), 3.57 
(m, 4H), 2.59 – 2.40 (m, 6H), 2.35 (dd, J = 14.4, 10.0 Hz, 1H), 2.15 (dd, J = 14.6, 10.4 Hz, 1H), 
1.93 – 1.80 (m, 8H), 1.48 (m, 18H), 1.46 (s, 3H), 1.43 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H), 1.32 (s, 
3H), 1.27 (m, 6H), 1.14 (s, 3H), 0.98 (s, 9H), 0.97 – 0.93 (m, 28H); 13C NMR (125 MHz, CDCl3) 
δ 195.8, 195.6, 171.1, 170.6, 165.1, 163.1, 152.3, 151.6, 81.3, 81.2, 80.7, 80.6, 80.5, 80.1, 80.0, 
78.2, 48.2, 47.3, 44.6, 41.7, 39.6, 39.5, 39.3, 39.2, 38.5, 37.9, 37.9, 33.0, 32.9, 28.1, 27.9, 27.8, 
27.5, 27.0, 26.9, 26.7, 26.6, 25.8, 25.6, 24.9, 24.9, 24.9, 24.5, 23.8, 21.3. 
 
To a solution of the reaction mixture from aldehyde 3.23 formation in CH2Cl2 (28 mL) was 
added (R, R)-trans-crotylsilane diamine reagent 3.24 (2.38 g, 4.19 mmol) and Sc(OTf)3 (138 mg, 
0.279 mmol). After 24 hours at room temperature, additional Sc(OTf)3 and reagent were added. 
After another 16 hours, the reaction was still incomplete as judged by 1H NMR. The solution was 
then cooled to 0°C and tetrabutylammonium fluoride (TBAF) trihydrate (879 mg, 2.79 mmol) was 
added portion-wise over 20 minutes. After about 3 hours, the reaction was concentrated and the 
residue purified via silica gel chromatography (5% EtOAc/hexanes) to afford 3.25 (658 mg, 37% 
over 3 steps) as a viscous yellow oil. 3.25 was a 2:1 mixture of diastereomers at silicon. (Another 
diastereomer that was formed in equal amount with the minor from unselective crotylation of one 
of the aldehyde diastereomers was removed via the silica gel chromatography.)  1H NMR (400 
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MHz, CDCl3) δ 5.76 (m, 3H), 5.06 – 4.89 (m, 6H), 4.39 (d, J = 2.3 Hz, 2H), 4.34 (d, J = 2.3 Hz, 
1H), 4.19 – 4.11 (m, 3H), 3.58 (m, 6H), 2.99 (d, J = 3.4 Hz, 1H), 2.95 (d, J = 3.1 Hz, 2H), 2.83 
(m, 3H), 2.52 (m, 6H), 2.30 (m, 3H), 1.99 (m, 3H), 1.82 (m, 12H), 1.76 – 1.61 (m, 5H), 1.57 – 
1.48 (m, 4H), 1.47 (m, 34H), 1.44 (m, 13H), 1.34 – 1.25 (m, 17H), 1.26 – 1.17 (m, 13H), 1.00 – 
0.97 (m, 57H); 13C NMR (125 MHz, CDCl3) δ 173.3, 173.1, 162.2, 138.9, 138.8, 134.6, 114.9, 
114.8, 80.7, 80.6, 80.4, 80.1, 79.9, 79.9, 79.7, 74.2, 74.1, 44.7, 41.8, 41.4, 41.3, 39.9, 39.8, 39.5, 
39.4, 38.7, 38.4, 38.3, 37.9, 37.6, 32.8, 32.7, 31.6, 29.8, 28.4, 28.2, 28.1, 28.1, 27.9, 27.7, 27.1, 
26.4, 26.1, 25.9, 25.5, 25.2, 25.1, 25.1, 25.0, 24.7, 24.4, 22.7, 18.3, 18.2, 14.1. 
 
To a solution of trimethylhydroquinone (515 mg, 3.39 mmol), quinuclidine hydrochloride 
(450 mg, 3.05 mmol), and silver fluoride (459 mg, 3.62 mmol) in benzonitrile (5.0 mL) was added 
3.25 (711 mg, 1.13 mmol) as a solution in benzonitrile (6.3 mL). The solution was purged with O2 
then the reaction was heated to 60°C (oil bath, external temperature) and stirred overnight under a 
balloon of O2. After 22 hours, the reaction was cooled to room temperature and diluted with CHCl3 
(15 mL). The solution was filtered through Celite, then washed with distilled water. The aqueous 
layer was extracted with CHCl3 (3 x 15 mL). The combined organics were washed with brine, 
dried over MgSO4, filtered, and concentrated. The residue was purified via silica gel 
chromatography (stepwise: 10% EtOAc/hexanes, 30% EtOAc/hexanes) to provide 3.27 (345 mg, 
75%) as a brown oil with >18:1 diastereomeric ratio (d.r.) with respect to the newly formed 
stereocenter at C6. 1H NMR (300 MHz, CDCl3) δ 5.87 (ddd, J = 17.8, 10.4, 7.7 Hz, 1H), 5.12 (dd, 
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J = 8.4, 1.5 Hz, 1H), 5.09 – 5.05 (m, 1H), 4.24 (dt, J = 10.0, 3.2 Hz, 1H), 3.61 (dt, J = 8.1, 2.6 Hz, 
1H), 3.53 (td, J = 6.6, 3.4 Hz, 2H), 3.36 (d, J = 3.5 Hz, 1H), 3.23 (dt, J = 8.8, 3.2 Hz, 1H), 2.54 (d, 
J = 2.6 Hz, 1H), 2.40 (dd, J = 16.1, 2.9 Hz, 1H), 2.31 (dd, J = 16.2, 9.7 Hz, 2H), 1.89 – 1.71 (m, 
3H), 1.47 (s, 9H), 1.43 – 1.29 (m, 2H), 1.23 (s, 3H), 1.10 (s, 3H), 1.03 (d, J = 6.8 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 219.7, 172.5, 141.2, 115.4, 81.8, 73.7, 72.9, 52.0, 48.4, 44.8, 41.3, 
37.4, 33.00, 28.2, 25.5, 24.7, 22.2, 19.2, 16.9; IR (film): 3494, 2971, 2932, 2872, 1706, 1457, 
1392, 1368, 1303, 1253, 1221, 1153, 1033, 997, 915, 765, 727, 650 cm-1; LRMS (FAB+) calcd 
C21H37ClO5Na [M+Na]+: 427.22, found 427.5; [α]20D -46.7 (c 0.45, CHCl3). 
 
To a cooled (-78°C) solution of 3.27 (345 mg, 0.852 mmol) in CH2Cl2 (8.8 mL) was added 
2,6-lutidine (0.61 mL, 5.27 mmol). TESOTf (0.40 mL, 1.76 mmol) was then added dropwise. After 
30 minutes, a second portion of TESOTf (0.40 mL, 1.76 mmol) was added and the cold bath was 
removed, allowing the reaction to warm to room temperature. After 2 hours, the reaction was 
diluted with Et2O (80 mL), washed with 5% aqueous KHSO4 (2 x 10 mL) then brine (15 mL), and 
then dried over Na2SO4 and concentrated. The residue was dissolved in aqueous THF (15 mL, 6:1 
THF/H2O) and treated with saturated aqueous NaHCO3 (2 mL). After stirring at room temperature 
for 20 minutes, the mixture was diluted with Et2O (20 mL) and acidified with 5% aqueous KHSO4 
(10 mL). The layers were separated then the aqueous layer extracted with Et2O (2 x 15 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to 
provide 3.28 as a mixture with TESOH. The crude product was used directly in the next step. For 
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characterization purpose, purification via silica gel chromatography (15% EtOAc/hexanes, pH 7 
buffered silica gel) provided 3.28 as a light yellow oil.1 1H NMR (500 MHz, CDCl3) δ 10.73 (bs, 
1H), 5.94 – 5.79 (m, 1H), 5.11 – 4.98 (m, 2H), 4.32 (dd, J = 7.4, 2.9 Hz, 1H), 3.86 (dd, J = 5.3, 
3.3 Hz, 1H), 3.50 (t, J = 6.6 Hz, 2H), 3.03 – 3.00 (m, 1H), 2.60 (dd, J = 16.6, 2.9 Hz, 1H), 2.33 
(dd, J = 16.6, 7.3 Hz, 1H), 2.20 – 2.13 (m, 1H), 1.76 – 1.59 (m, 3H), 1.51 – 1.45 (m, 1H), 1.39 – 
1.28 (m, 2H), 1.21 (s, 3H), 1.12 (s, 3H), 1.05 (s, 3H), 0.98 – 0.94 (m, 18H), 0.71 – 0.52 (m, 12H). 
13C NMR (125 MHz, CDCl3) δ 216.6, 177.0, 140.2, 115.5, 75.8, 74.3, 53.3, 51.6, 45.0, 44.3, 39.6, 
33.2, 27.0, 25.4, 24.2, 19.5, 18.7, 7.3, 7.1, 5.6, 5.3; IR (film): 2955, 2877, 2916, 1709, 1692, 1458, 
1416, 1302, 1238, 1093, 1003, 914, 731 cm-1; LRMS (FAB+) calcd C27H57ClO5Si2 [M+H]+: 
577.34, found 577.95; [α]24D -22.6 (c 1.43, CHCl3). 
 To a cooled (0°C) solution of dried 3.8 (207 mg, 1.23 mmol) in CH2Cl2 (5.0 mL) was added 
solid DMAP (172 mg, 1.41 mmol) and EDCI (270 mg, 1.41 mmol). After stirring for 15 minutes, 
the crude 3.28 (azeotroped 3x with benzene) was added slowly as a solution in CH2Cl2 (7.6 mL). 
After 5 minutes, the cooling bath was removed and the reaction was allowed to warm to ambient 
temperature. After 4 hours, the reaction mixture was filtered directly though a plug of silica gel 
(10% EtOAc/hexanes). Purification via silica gel chromatography (2.5% EtOAc/hexanes) 
provided 3.29 (453 mg, 73% over 2 steps). 1H NMR (500 MHz, CDCl3) δ 5.86 (ddd, J = 17.2, 
10.6, 8.1 Hz, 1H), 5.83 – 5.64 (m, 1H), 5.19 (t, J = 7.2 Hz, 1H), 5.07 – 4.99 (m, 4H), 4.97 (t, J = 
6.2 Hz, 1H), 4.28 (dd, J = 7.3, 2.8 Hz, 1H), 3.84 (dd, J = 4.9, 3.5 Hz, 1H), 3.50 (t, J = 6.6 Hz, 2H), 
3.04 – 3.01 (m, 1H), 2.80 – 2.73 (m, 2H), 2.70 (dd, J = 17.2, 2.9 Hz, 1H), 2.48 (t, J = 6.8 Hz, 2H), 
2.39 (dd, J = 17.2, 7.4 Hz, 1H), 2.21 – 2.15 (m, 1H), 2.13 (s, 3H), 1.76 – 1.62 (m, 6H), 1.50 – 1.46 
(m, 1H), 1.34 (d, J = 8.0 Hz, 2H), 1.24 (s, 4H), 1.10 (s, 3H), 1.04 (d, J = 7.0 Hz, 3H), 0.98 – 0.92 
                                                            
1 Procedures for the synthesis of compounds 3.29 – 3.33 adapted from: Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; 
Chou, T.-C.; Dong, H.; Tong, W. P.; Danishefsky, S. J. J. Am. Chem. Soc. 2003, 125, 2899-2901. 
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(m, 18H), 0.61 (q, J = 8.2 Hz, 12H); 13C NMR (125 MHz, CDCl3) δ 216.1, 205.3, 172.1, 140.3, 
137.4, 135.4, 119.0, 115.8, 115.4, 78.8, 75.8, 74.7, 53.0, 51.8, 45.0, 44.4, 39.5, 36.5, 33.3, 29.2, 
26.8, 26.6, 25.4, 24.0, 23.7, 20.4, 18.6, 7.3, 7.2, 5.6, 5.2; IR (film): 2955, 2877, 2911, 1731, 1693, 
1638, 1458, 1416, 1379, 1295, 1238, 1161, 1092, 1003, 913, 728 cm-1; HRMS (FAB+) calcd 
C39H70ClO6Si2 [M-H]+: 725.45, found 725.4413; [α]24D -24.5 (c 0.84, CHCl3). 
 
 To a refluxing solution of 3.29 (93 mg, 0.128 mmol) in toluene (250 mL) was added a 
solution of Grubbs second generation catalyst (16 mg, 0.0192 mmol) in toluene (10 mL). After 30 
minutes, the solution was cooled to 0°C and then filtered through a plug of silica gel (hexanes then 
CH2Cl2). The combined filtrate was concentrated then the residue purified via silica gel 
chromatography (7.5% EtOAc/hexanes) to provide 3.30 (60 mg, 66%) as a 10:1 mixture with an 
unidentified but related impurity. Further chromatography provided pure product for 
characterization. 1H NMR (400 MHz, CDCl3) δ 5.58 (dd, J = 15.8, 8.1 Hz, 1H), 5.34 (t, J = 5.9 
Hz, 1H), 5.19 (t, J = 8.0 Hz, 1H), 4.96 (dd, J = 9.2, 2.4 Hz, 1H), 4.17 (dd, J = 9.7, 2.5 Hz, 1H), 
4.10 (d, J = 9.7 Hz, 1H), 3.61 – 3.42 (m, 2H), 3.17 – 3.04 (m, 1H), 3.03 – 2.89 (m, 2H), 2.72 (dd, 
J = 15.4, 2.6 Hz, 1H), 2.62 – 2.52 (m, 1H), 2.52 – 2.43 (m, 1H), 2.38 (dd, J = 14.5, 7.5 Hz, 1H), 
2.29 (p, J = 7.1 Hz, 1H), 2.21 (s, 3H), 1.78 – 1.67 (m, 3H), 1.66 (s, 3H), 1.54 – 1.38 (m, 2H), 1.27 
– 1.19 (m, 1H), 1.17 (s, 3H), 1.11 (s, 3H), 1.05 (d, J = 7.1 Hz, 3H), 1.00 (t, J = 7.9 Hz, 9H), 0.91 
(t, J = 7.9 Hz, 9H), 0.67 (q, J = 7.9 Hz, 6H), 0.57 (q, J = 8.1 Hz, 6H); 13C NMR (125 MHz, CDCl3) 
δ 213.9, 204.8, 171.4, 140.3, 132.6, 129.7, 118.6, 79.2, 77.0, 75.8, 54.0, 53.7, 44.8, 41.0, 40.3, 
34.9, 33.1, 29.1, 28.3, 26.6, 23.8, 23.7, 23.6, 23.5, 21.4, 7.3, 7.1, 5.8, 5.4. IR (film): 2955, 2877, 
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2911, 1744, 1730, 1692, 1459, 1415, 1380, 1357, 1305, 1239, 1158, 1102, 1007, 855, 728 cm-1; 
LRMS (FAB+) calcd C37H68ClO6Si2 [M+H]+: 699.42, found 699.46; [α]22D -10.0 (c 0.71, CHCl3). 
 
 To a cooled (0°C) solution of Wittig reagent 3.7 (180 mg, 0.515 mmol) in THF (4.6 mL) 
was added KHMDS (1.03 mL, 0.515 mmol). The mixture was stirred for 30 minutes, then cooled 
to -78°C. To the solution was added 3.30 (60 mg, 0.0858 mmol) as a solution in THF (4.0 mL), 
and the resulting mixture allowed to warm to about -20°C over the course of 1.5 hour. The reaction 
was quenched with sat. aq. NH4Cl (8 mL) and extracted with EtOAc (3 x 15 mL). The combined 
organic layers were dried over Na2SO4 and concentrated. The residue was purified via silica gel 
chromatography (4% EtOAc/hexanes) to afford 3.31 (53 mg, 78%) as a 14:1 mixture with the Z-
isomer. Pure compound was obtained through further silica gel chromatography for 
characterization purposes. 1H NMR (400 MHz, CDCl3) δ 6.96 (s, 1H), 6.56 (s, 1H), 5.66 (dd, J = 
15.7, 8.1 Hz, 1H), 5.40 – 5.28 (m, 2H), 5.22 (dd, J = 10.0, 5.7 Hz, 1H), 4.31 (dd, J = 9.5, 1.8 Hz, 
1H), 4.11 (d, J = 9.7 Hz, 1H), 3.56 – 3.40 (m, 2H), 3.15 (dd, J = 14.5, 6.8 Hz, 1H), 3.00 (dt, J = 
9.6, 4.0 Hz, 1H), 2.71 (s, 3H), 2.71 – 2.62 (m, 2H), 2.47 (dd, J = 14.6, 2.1 Hz, 1H), 2.41 (dd, J = 
14.6, 5.7 Hz, 1H), 2.24 – 2.13 (m, 2H), 2.13 (d, J = 1.3 Hz, 3H), 1.90 – 1.78 (m, 1H), 1.75 – 1.61 
(m, 5H), 1.54 – 1.37 (m, 2H), 1.22 – 1.12 (m, 1H), 1.11 (s, 3H), 1.07 (d, J = 7.1 Hz, 3H), 1.04 (s, 
3H), 1.01 (t, J = 7.9 Hz, 9H), 0.88 (t, J = 7.9 Hz, 9H), 0.68 (q, J = 8.0 Hz, 6H), 0.56 (qd, J = 8.3, 
7.9, 1.7 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 214.9, 170.7, 164.7, 152.7, 138.1, 138.1, 132.0, 
129.6, 120.9, 120.4, 116.3, 79.3, 76.3, 74.8, 53.9, 53.8, 44.8, 41.2, 41.1, 35.4, 33.3, 33.2, 28.1, 
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24.5, 23.7, 23.5, 21.9, 21.7, 19.4, 15.1, 7.4, 7.1, 5.9, 5.5; IR (film): 2956, 2877, 2911, 1739, 1690, 
1459, 1414, 1379, 1240, 1181, 1100, 1031, 1009, 971, 731 cm-1; LRMS (FAB+) calcd 
C42H73ClNO5SSi2 [M+H]+: 794.44, found 794.5; [α]21D -11.5 (c 0.66, CHCl3). 
 
 To a cooled (0°C) solution of 3.31 (42 mg, 0.0528 mmol) in THF (1.1 mL) in a plastic tube 
was added HF·pyridine (0.24 mL). After addition, the reaction was warmed to ambient 
temperature and stirred for 3 hours. The reaction was cooled to 0°C and TMSOMe (2.5 mL) was 
added dropwise. After the addition, the reaction was warmed to ambient temperature and stirred 
for 15 minutes. The reaction was concentrated and dried under high vacuum, then the residue 
purified by silica gel chromatography (10% EtOAc/DCM) to provide 3.32 (26 mg, 87%). 1H NMR 
(400 MHz, CDCl3) δ 6.97 (s, 1H), 6.54 (s, 1H), 5.58 (ddd, J = 15.7, 7.6, 5.0 Hz, 1H), 5.47 (dd, J 
= 15.7, 7.3 Hz, 1H), 5.33 (dd, J = 9.0, 2.9 Hz, 1H), 5.12 (dd, J = 9.2, 5.3 Hz, 1H), 4.29 (dt, J = 8.2, 
3.6 Hz, 1H), 3.77 – 3.67 (m, 1H), 3.51 (td, J = 6.6, 4.1 Hz, 2H), 3.36 – 3.24 (m, 1H), 3.21 (d, J = 
4.8 Hz, 1H), 2.94 (dd, J = 14.8, 7.6 Hz, 1H), 2.70 (s, 3H), 2.68 – 2.56 (m, 2H), 2.53 (dd, J = 20.7, 
4.1 Hz, 1H), 2.48 – 2.40 (m, 2H), 2.42 – 2.30 (m, 2H), 2.08 (s, 2H), 1.95 – 1.85 (m, 1H), 1.80 – 
1.67 (m, 5H), 1.55 – 1.37 (m, 1H), 1.39 – 1.26 (m, 6H), 1.09 (d, J = 6.9 Hz, 3H), 1.01 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 217.3, 170.8, 165.1, 152.3, 138.0, 137.8, 131.3, 129.9, 120.5, 119.7, 
116.2, 78.4, 75.5, 72.7, 53.0, 51.1, 44.8, 39.3, 39.2, 35.3, 32.9, 32.3, 28.0, 24.6, 23.9, 21.6, 20.6, 
19.4, 19.3, 15.9; IR (film): 3460, 2964, 2930, 2871, 1730, 1687, 1506, 1446, 1377, 1293, 1252, 
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1187, 1155, 1044, 977, 755 cm-1; LRMS (FAB+) calcd C30H45ClNO5S [M+H]+: 566.26, found 
566.32; [α]22D -82.4 (c 0.75, CHCl3). 
 
To a solution of 3.32 (26 mg, 0.0459 mmol) and TrisNHNH2 (548 mg, 1.84 mmol) in 
ClCH2CH2Cl (13 mL) at 50°C (external temp, oil bath) was added NEt3 (0.26 mL, 1.84 mmol). 
After 8 hours, the reaction was cooled to ambient temperature and diluted with EtOAc, then filtered 
through a plug of silica gel. The filtrate was concentrated, then the residue purified via silica gel 
chromatography (30% EtOAc/hexanes) to provide 3.33 (25 mg, 96%). 1H NMR (500 MHz, 
CDCl3) δ 6.95 (s, 1H), 6.56 (s, 1H), 5.23 (dd, J = 10.3, 2.1 Hz, 1H), 5.12 (dd, J = 10.0, 4.6 Hz, 
1H), 4.25 (d, J = 10.6 Hz, 1H), 3.77 – 3.68 (m, 1H), 3.58 – 3.42 (m, 3H), 3.29 (dt, J = 7.9, 4.1 Hz, 
1H), 2.70 (s, 3H), 2.68 – 2.60 (m, 1H), 2.57 (d, J = 3.7 Hz, 1H), 2.48 (dd, J = 14.8, 10.4 Hz, 1H), 
2.39 (dd, J = 14.8, 2.8 Hz, 1H), 2.33 – 2.27 (m, 1H), 2.27 – 2.21 (m, 1H), 2.07 (s, 3H), 1.91 – 1.70 
(m, 6H), 1.69 (s, 3H), 1.66 – 1.56 (m, 1H), 1.48 – 1.37 (m, 3H), 1.33 (s, 3H), 1.29 – 1.21 (m, 2H), 
1.08 (s, 3H), 1.04 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 219.2, 170.7, 165.2, 152.2, 
139.6, 139.2, 120.4, 119.5, 115.9, 79.4, 74.4, 72.6, 53.5, 48.9, 44.8, 39.6, 36.2, 33.0, 32.8, 32.3, 
30.7, 27.0, 25.1, 25.0, 23.8, 22.1, 19.7, 19.3, 17.1, 15.9; IR (film): 3474, 2960, 2932, 2871, 1731, 
1686, 1507, 1464, 1446, 1377, 1337, 1291, 1252, 1187, 1151, 1072, 1029, 981, 755 cm-1; LRMS 




To a solution of 3.33 (25 mg, 0.044 mmol) in DMF (0.5 mL) was added NaN3 (3.4 mg, 
0.0523 mmol). The reaction was heated to 60°C (external temp, oil bath) and stirred overnight. 
After 24 hours, the reaction was cooled to ambient temperature, then diluted with EtOAc and 
deionized water. The layers were separated and the aqueous layer extracted with EtOAc (3 x 5 
mL). The combined organic layers were dried over Na2SO4 and concentrated. The residue was 
purified via silica gel chromatography to provide 3.34 (25 mg, 99%). 1H NMR (400 MHz, CDCl3) 
δ 6.95 (s, 1H), 6.56 (s, 0H), 5.22 (d, J = 9.8 Hz, 1H), 5.11 (dd, J = 10.0, 4.8 Hz, 1H), 4.31 – 4.23 
(m, 1H), 3.75 – 3.65 (m, 2H), 3.59 (d, J = 5.6 Hz, 1H), 3.32 – 3.23 (m, 3H), 2.69 (s, 3H), 2.67 – 
2.61 (m, 1H), 2.62 – 2.56 (m, 2H), 2.48 (dd, J = 14.8, 10.4 Hz, 1H), 2.38 (dd, J = 14.8, 2.9 Hz, 
1H), 2.33 – 2.26 (m, 1H), 2.28 – 2.18 (m, 2H), 2.06 (d, J = 1.3 Hz, 3H), 1.88 – 1.71 (m, 4H), 1.69 
(s, 2H), 1.67 – 1.59 (m, 3H), 1.58 – 1.51 (m, 1H), 1.37 – 1.28 (m, 6H), 1.07 (s, 3H), 1.04 (d, J = 
7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 219.1, 170.7, 165.1, 152.2, 139.6, 139.2, 120.4, 119.5, 
115.9, 79.3, 74.4, 72.5, 53.4, 51.3, 48.9, 39.6, 36.2, 32.8, 32.3, 30.7, 29.5, 27.3, 25.0, 23.7, 22.0, 
19.7, 19.2, 17.1, 15.9;  IR (film): 3464, 2955, 2927, 2854, 2096, 1733, 1685, 1463, 1378, 1289, 
1261, 1184, 1148, 1075, 1029, 803 cm-1; LRMS (FAB+) calcd C30H47N4O5S [M+H]+: 575.32, 




To a cooled (-78°C) solution of 3.34 (25 mg, 0.0433 mmol) in CH2Cl2 (2.2 mL) was added 
a cooled (-78°C) solution of DMDO (1.5 mL, 0.130 mmol, 0.086 M in acetone) via cannula. After 
the addition was complete, the solution was warmed to -50°C and stirred for 2 hours. Additional 
DMDO solution was added since there was starting material remaining. After another 2 hours the 
reaction seemed to have stalled, so dimethyl sulfide was added to quench any remaining DMDO, 
then the solution concentrated. The residue was purified via silica gel chromatography (pH 7 
buffered silica gel, 40% EtOAc/hexanes) to provide 3.35 (14.5 mg, 59%).2 1H NMR (400 MHz, 
CDCl3) δ 6.97 (s, 1H), 6.55 (s, 1H), 5.46 (t, J = 5.0 Hz, 1H), 4.61 (d, J = 5.7 Hz, 1H), 4.27 (ddd, J 
= 10.2, 5.5, 2.5 Hz, 1H), 3.63 (q, J = 5.3 Hz, 1H), 3.44 (dt, J = 8.3, 3.9 Hz, 1H), 3.26 (td, J = 6.7, 
4.1 Hz, 2H), 2.87 (d, J = 5.8 Hz, 1H), 2.80 (t, J = 6.2 Hz, 1H), 2.70 (s, 3H), 2.56 (dd, J = 14.3, 
10.3 Hz, 1H), 2.41 (dd, J = 14.3, 2.6 Hz, 1H), 2.10 (d, J = 1.3 Hz, 3H), 2.02 (t, J = 5.7 Hz, 2H), 
1.92 – 1.77 (m, 1H), 1.78 – 1.69 (m, 2H), 1.64 – 1.50 (m, 4H), 1.53 – 1.41 (m, 1H), 1.37 (s, 3H), 
1.33 – 1.22 (m, 9H), 1.03 (s, 3H), 0.99 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 220.0, 
170.7, 165.2, 152.1, 137.0, 119.4, 116.4, 76.7, 75.5, 73.5, 61.4, 61.0, 53.2, 51.3, 50.4, 39.0, 34.8, 
32.2, 31.7, 30.1, 29.4, 28.3, 25.2, 22.3, 21.2, 21.1, 20.5, 19.3, 17.5, 16.2; IR (film): 3446, 2960, 
2926, 2859, 2095, 1735, 1685, 1504, 1463, 1379, 1345, 1289, 1259, 1183, 1144, 1050, 1025, 978, 
803, 735 cm-1; LRMS (FAB+) calcd C30H47N4O6S [M+H]+: 591.31, found 591.45; [α]23D -71.6 (c 
0.53, CHCl3). 
                                                            




 To 3.35 (2.4 mg, 0.00406 mmol) was added 3.38 (1.7 mg, 0.00406 mmol) as a solution in 
a 1:2 mixture of CD3CN:D2O (0.5 mL). This was left to stir overnight at ambient temperature, then 
the next day loaded directly onto a plug of silica gel and filtered (EtOAc then acetone). The filtrate 
was concentrated, then the residue purified via silica gel chromatography (4% MeOH/CH2Cl2) to 
provide 3.36 (4.0 mg, 97%). 1H NMR (500 MHz, CDCl3) δ 6.97 (s, 1H), 6.56 (s, 1H), 5.95 (s, 1H), 
5.46 (dd, J = 6.5, 3.5 Hz, 1H), 5.18 (s, 1H), 4.42 (s, 1H), 4.28 – 4.18 (m, 3H), 4.16 (d, J = 8.0 Hz, 
2H), 3.69 – 3.54 (m, 9H), 3.46 (q, J = 5.3 Hz, 2H), 3.43 – 3.33 (m, 5H), 3.17 – 3.05 (m, 3H), 2.93 
– 2.83 (m, 2H), 2.81 (t, J = 6.2 Hz, 1H), 2.70 (s, 3H), 2.69 – 2.61 (m, 1H), 2.55 (dd, J = 14.3, 10.1 
Hz, 1H), 2.41 (dd, J = 14.4, 2.9 Hz, 1H), 2.27 – 2.19 (m, 1H), 2.17 (t, J = 7.6 Hz, 2H), 2.10 (d, J 
= 1.2 Hz, 3H), 2.06 – 1.97 (m, 2H), 1.96 – 1.84 (m, 1H), 1.85 – 1.75 (m, 1H), 1.79 – 1.69 (m, 1H), 
1.68 – 1.61 (m, 2H), 1.60 – 1.47 (m, 6H), 1.47 – 1.35 (m, 1H), 1.37 – 1.28 (m, 7H), 1.27 (s, 4H), 
1.26 – 1.15 (m, 3H), 1.03 – 0.97 (m, 5H), 0.89 (t, J = 6.9 Hz, 4H); 13C NMR (125 MHz, CDCl3) δ 
219.5, 170.7, 165.2, 156.8, 152.1, 145.0, 144.9, 137.0, 132.8, 119.6, 116.4, 76.7, 75.0, 73.5, 70.4, 
70.4, 70.2, 70.2, 62.8, 61.4, 61.2, 53.1, 53.1, 50.3, 47.4, 41.0, 39.3, 39.1, 36.9, 35.0, 32.1, 31.9, 
31.6, 30.3, 29.9, 27.7, 26.1, 25.6, 24.0, 23.2, 22.8, 22.6, 22.5, 22.3, 21.6, 21.1, 20.5, 20.2, 19.6, 
19.3, 17.9, 17.7, 16.1, 14.1; IR (film): 3341, 2956, 2930, 2869, 1713, 1696, 1649, 1549, 1535, 
96 
 
1466, 1379, 1253, 1143, 1100, 1048, 1024, 753 cm-1; LRMS (FAB+) calcd C53H85N6O11S [M+H]+: 
1013.59, found 1013.79; [α]22D -31.9 (c 0.44, CHCl3). 
 
 To 3.35 (5.6 mg, 0.00948 mmol) was added phosphinothioester 3.39 (75 mg, 0.260 mmol) 
as a solution in 1:1 THF:D2O (2 mL). The reaction was allowed to stir overnight at ambient 
temperature. Most of the starting material transformed into an unidentified side product, but a 
small amount of 3.37 (0.7 mg, 11% yield) was isolated from silica gel chromatography (5% 
MeOH/CH2Cl2). 1H NMR (400 MHz, CHCl3) δ 6.97 (s, 1H), 6.56 (s, 1H), 5.53 – 5.39 (m, 2H), 
4.51 (d, J = 5.9 Hz, 1H), 4.29 – 4.19 (m, 1H), 3.72 – 3.60 (m, 1H), 3.42 (dt, J = 8.3, 4.3 Hz, 1H), 
3.33 – 3.12 (m, 2H), 3.01 (d, J = 5.7 Hz, 1H), 2.81 (t, J = 6.2 Hz, 1H), 2.70 (s, 3H), 2.56 (dd, J = 
14.4, 10.1 Hz, 1H), 2.42 (dd, J = 14.4, 2.9 Hz, 1H), 2.10 (d, J = 1.3 Hz, 3H), 2.06 – 1.97 (m, 1H), 
1.97 (s, 3H), 1.94 – 1.79 (m, 1H), 1.74 – 1.63 (m, 1H), 1.54 – 1.37 (m, 10H), 1.35 (s, 3H), 1.31 – 
1.17 (m, 8H), 1.03 (s, 3H), 0.99 (d, J = 6.8 Hz, 3H); LRMS (APCI+) calcd C32H51N2O7S [M+H]+: 






































































Chapter 4: A New Approach to the Rapid Synthesis of 
Polypropionate Stereotriad Building Blocks1  
4.1 Introduction 
 
Scheme 4.1 Utility of Polypropionate Building Blocks for Natural Product Synthesis 
Due to their synthetic versatility, stereotriad fragments such as 4.1 and 4.2 have commonly 
been utilized as building blocks in the construction of many nonaromatic polyketide natural 
products. Since its full development by Roush in 1987,2,3 total synthesis efforts that incorporate 
these stereotriad building blocks have relied heavily on the “Roche ester” approach for their 
formation.4–7 For example, most of the reported syntheses of related natural products 
discodermolide and dictyostatin (shown in Scheme 4.1) utilize the “Roche ester” approach,8 
including the 60 gram production of discodermolide that has been reported by Novartis.9 In 
employing this approach, the hydroxyl group of the commercially available Roche ester 4.3 is first 
protected and then the ester moiety reduced to access the corresponding aldehyde 4.4. 
Diastereoselective crotylation provides the stereotriad-containing product 4.5, but further 
protecting group manipulations and redox adjustments are required to form useful building block 
4.6 (Scheme 4.2). Of the six or seven steps required to obtain the stereotriad building block by this 
approach, only one is a carbon-carbon bond forming step that installs two stereocenters. The third 
stereocenter is purchased, and the rest of the steps are redox and protecting group manipulations 
that are required to access useful intermediates, as opposed to productive carbon-carbon bond-





Scheme 4.2 “Roche Ester” Approach to Stereotriad Synthesis 
An alternative approach to these stereotriad building blocks has recently been reported by 
our group as part of a highly step-economical synthesis of dictyostatin.10 In this method, vinyl 
acetals can be converted into the functionalized building blocks through a three-step process 
utilizing Landis’ method for asymmetric hydroformylation11 to set the α-stereocenter followed by 
crotylation to complete the stereotriad (Scheme 4.3). While this approach represents a much more 
direct synthesis of the building blocks, the regioselectivities of asymmetric hydroformylation 
reaction are only moderate to poor, and the required Landis ligand was very expensive and now 
no longer commercially available. Given these issues, we were interested in exploring another 
approach to the stereotriad building blocks 4.1 and 4.2. 
 
Scheme 4.3 Asymmetric Hydroformylation Approach to Stereotriad Building Blocks 
 After completing our synthesis of the C1-C9 fragment of the epothilones, we considered 
that our new intermolecular crotylation tactic may lend itself to a more general approach to 
stereotriad synthesis than the previous intramolecular tandem silylformylation-crotylsilylation 
approach could. The intramolecular approach required the use of a homopropargylic alcohol and 
was thus useful for access to 1,5-anti-diol moieties, though the level of selectivity was dependent 
on the substrate. It was also limited to an anti relationship for the stereocenters set by the 
crotylation reaction because access to the bis-trans-crotylsilane has not been possible. On the other 




crotylation reagent, which can provide access to any combination of the two new stereocenters, 
regardless of the existing stereochemistry in the molecule. The potential to apply the “aprotic” 
Tamao oxidation conditions to substrates other than the epothilone fragment is another advance, 
which has provided a switch in diastereoselectivity relative to the standard Tamao oxidation 
conditions for setting the third stereocenter. With all of these tools now at our disposal, it seemed 
that we could apply our strategy more generally, for potential access to any combination of 
stereotriad stereocenters. 
 We became interested in applying our new strategy towards a highly step-economical and 
scalable synthesis of stereotriad building blocks 4.1 and 4.2 due to their vast synthetic utility. 
Access to these products would also represent the most generalized example of such a strategy 
because the alkyne substrate would now have only a methyl group or hydrogen atom substituent, 
as opposed to a more elaborate system. For our approach we envisioned a three step sequence, 
starting with the intermolecular silylformylation of an alkyne 4.7 or 4.8 with a silane 4.9, followed 
by crotylation with either (S,S)- or (R,R)- and cis- or trans-crotylation reagent, and finally 
oxidation using the standard (protic) or “aprotic” Tamao oxidation conditions to provide building 
block 4.1 or 4.2 with any combination of the three stereocenters (Scheme 4.4). 
  
Scheme 4.4 Proposed Carbonylation-Crotylation Approach to Stereotriad Building Blocks 
Since the α-stereocenter set during the Tamao oxidation would be induced by the existing 
stereochemistry of the neighboring hydroxyl group (β-stereocenter), this approach would be able 




reagent). Each step of this proposed synthesis involves either a carbon-carbon bond-forming step 
or sets a stereocenter (and installs the ketone moiety), so they can all be considered productive 
steps, without the need for oxidation adjustments or protecting group manipulations along the way. 
4.2 Intermolecular Silylformylation-Crotylation of 2-Butyne 
In approaching this synthesis, we knew that the choice of silane would be a key component 
for the success of our strategy. This silane would need to react efficiently in an intermolecular 
silylformylation reaction, provide stability for effective isolation of the crotylation product, and be 
activated enough towards oxidative cleavage in the Tamao oxidation. Since the oxidation step 
typically requires that the silicon have at least one heteroatom substituent, we decided to begin by 
investigating alkoxysilanes 4.10 (Table 4.1). Readily available dimethylethoxysilane 4.10a did not 
undergo efficient silylformylation with 2-butyne, even over the course of 45 hours (entry 1). It is 
our working assumption that most, if not all, of the formation of product 4.12 occurs from 
hydrosilylation after the Parr bomb apparatus has been vented to release the CO pressure. Thus, 
the amount of 4.12 present can be used as a metric for the approximate amount of starting material 
remaining prior to venting. Based on this assumption, the conversion of starting materials to 
product 4.11a was far from complete. 
Given Matsuda’s report that silylformylation of a given alkyne can proceed approximately 
10 times faster with a silane that has a phenyl substituent than with a trialkyl silane,12 we decided 
to try diphenylethoxysilane 4.10b. While this change seemed to improve the rate of the reaction, 
it was still incomplete after 24 hours using 5 mol% of the rhodium catalyst (Table 4.1, entry 2). 
The use of acetonitrile instead of benzene as the solvent further increased the rate of the reaction. 
Unfortunately, along with this rate enhancement we also saw significant production of two new 




characterization, and a hemiacetal side product 4.13b, which is presumably formed via 
rearrangement of the silylformylation product and has been previously reported for alkoxysilane 
substrates.12 
Table 4.1 Optimization of the Silylformylation of 2-Butyne 
 
Utilizing a bulkier alkoxy group on the silane in the hopes of slowing down rearrangement 
of the product, we found that diphenylisopropxysilane 4.10c seemed to do just that, providing the 
desired product 4.11c in the absence of 4.13c within 20 hours (entry 4). This came with an increase 
in the silane-derived side product 4.14c, however. After further optimization, we found we could 
minimize the production of this side product and lower the catalyst loading to 2 mol % of 
Rh(acac)(CO)2 by using benzonitrile as the solvent (entry 5). It was these conditions that we chose 
to use in moving forward with our synthesis of stereotriad building blocks 4.2. 
In approaching the crotylation step, we hoped to use the unpurified product from the 
silylformylation as we had previously done in our synthesis of the C1-C9 epothilone fragment. We 
found that following silylformylation, we could directly dilute the benzonitrile solution with 




scandium(III) triflate13 as before, without a problem. Quenching this reaction with tetra-n-
butylammonium fluoride trihydrate resulted in cyclization to form 4.17 or 4.18, which we could 
isolate efficiently via chromatography. Final optimized conditions were able to provide syn 
crotylation product 4.17 in 70% yield over two steps with 93% ee and anti crotylation product 4.18 
in 67% yield over 2 steps with 95% ee, both demonstrated on scale to provide more than 4.5 grams 
of each product (Scheme 4.5). 
 
Scheme 4.5 Optimized Conditions for the 1-Pot Silylformylation-Crotylation of 2-Butyne 
4.3 Optimization of the Standard and “Aprotic” Tamao Oxidation Conditions 
With an efficient and highly enantioselective synthesis of 4.17 and 4.18 established, we 
were able to move forward to investigate the Tamao oxidation of these substrates using both the 
standard and “aprotic” conditions. It was our hope that the diastereochemical switch in the 
tautomerization selectivity that was established by the development of the syn-selective “aprotic” 
Tamao oxidation conditions for the C1-C9 epothilone fragment14 would extend to these new 




Table 4.2 Optimization of the Standard (Protic) Tamao Oxidation Condition for 4.17 
 
Examining the standard (protic) Tamao oxidation conditions using the syn crotylation 
product 4.17, we found that we were able to form the desired anti product 4.19 with high 
diastereoselectivity but moderate yields when utilizing potassium bicarbonate as the base (Table 
4.2, entry 1). Alternatively, we obtained higher yields but lower selectivity using potassium 
fluoride as a fluoride source in place of base (entry 2). Modifying the fluoride conditions in the 
hopes of maintaining a good yield but improving the diastereoselectivity, we determined that 
modulation of the solvent ratio of tetrahydrofuran and isopropanol decreased the selectivity 
(entries 3 and 4), but lowering the temperature to 0°C was able to boost the selectivity to form 4.19 
in 84% yield and 18:1 d.r. (entry 5). Applying these conditions to the anti crotylation product 4.18, 
the selectivity was slightly eroded to provide the anti, anti stereotriad product 4.20 in 87% yield 
and 9:1 d.r. (Scheme 4.6). 
 
Scheme 4.6 Standard Tamao Oxidation of 4.18 
Turning next to the “aprotic” Tamao oxidation conditions, we found that our previously 




diastereoselectivity, providing the syn, syn stereotriad product 4.21 in 2.5:1 d.r. and the syn, anti 
stereotriad product 4.22 in 1.4:1 d.r. As observed previously while optimizing these conditions for 
the C1-C9 epothilone fragment synthesis, increasing the substitution of the hydroquinone by 
exchanging 2,3-dimethylhydroquinone for trimethylhydroquinone improved the efficiency. Again, 
we believe that this effect can be explained by the higher concentration of active oxidant present 
in our reaction due to the increased rate of its production.15 The increased efficiency of the reaction 
allowed us to reduce the temperature of the reaction (from 60°C to ambient temperature) and 
improve the diastereoselectivity to ultimately obtain the syn-syn product 4.21 in 75% yield and 6:1 
d.r. and the syn-anti product 4.22 in 71% yield and 3:1 d.r. (Scheme 4.7). While these selectivities 
show that the “aprotic” Tamao oxidation conditions are not as general as we hoped, optimization 
provided a vast improvement over the initial results utilizing our previous conditions. 
 
Scheme 4.7 Optimized Conditions for “Aprotic” Tamao Oxidation to Form 4.21 and 4.22 
4.4 Utilization of Propyne Substrate Towards the Synthesis of Aldehyde Building Blocks 
As the corresponding aldehyde building blocks 4.1 might be even more generally useful 
for synthetic use, we aimed to extend our approach with propyne in the place of our previous 2-
butyne substrate which could provide the corresponding aldehyde products. Since our desired 
regioselectivity was well-precedented and the reduced steric hindrance expected to require milder 
conditions,12,16 we were hopeful that the silylformylation reaction with propyne might provide a 




silylformylation of propyne with diphenylisopropoxysilane 4.10c utilizing a lower catalyst loading 
and with decreased temperature, pressure, and reaction time relative to our optimized conditions 
for 2-butyne. In addition, we did not see any formation of the previously observed silane-derived 
side product 4.14c (see Table 4.1). As before, we were able to directly dilute the silylformylation 
reaction mixture with methylene chloride and apply our cis- or trans- crotylation reagents 4.15 or 
4.16 with catalytic scandium(III) triflate, followed by a tetra-n-butylammonium fluoride trihydrate 
quench to provide the cyclized products 4.24 and 4.25 in excellent overall yields and selectivities 
(Scheme 4.8). These reactions were demonstrated on gram scale in the indicated yields and 
selectivities. 
 
Scheme 4.8 Optimized Silylformylation-Crotylation of Propyne 
 In applying our previously optimized conditions for the standard Tamao oxidation to these 
new substrates 4.24 and 4.25, we found a decrease in selectivity and yield relative to the previous 
substrates 4.17 and 4.18. Exploring alternative conditions, we found that the use of potassium 
bicarbonate provided higher diastereoselectivities but lower yields than the potassium fluoride 




yield was only slightly lower, so when taking into account both the selectivity and the yield, the 
potassium bicarbonate conditions seemed to give the better overall result for these substrates. With 
fully optimized conditions for the standard Tamao oxidation, 4.24 and 4.25 were each 
demonstrated on 500 mg scale to provide the anti, syn product 4.26 and anti, anti product 4.27, 
respectively, in good yields and excellent diastereoselectivities (Scheme 4.9). 
 
Scheme 4.9 Optimized Standard Tamao Oxidation Conditions for Aldehyde Stereotriads 
Unfortunately, applying our optimized aprotic Tamao oxidation conditions to 4.24 gave 
the syn, syn product 4.28 in only moderate yield and poor diastereoselectivity, while the reaction 
of 4.25 was inefficient and nonselective (Scheme 4.10). 
 
Scheme 4.10 “Aprotic” Tamao Oxidation Results 
4.5  Observed Tamao Oxidation Selectivity Trends 
  Two interesting selectivity trends can be noted from our Tamao oxidation results. First, we 
found that for each substrate pair (i.e. 4.17/4.18 and 4.24/4.25), the diastereoselectivity was 




product 4.18 or 4.25 for both the standard and “aprotic” Tamao oxidation conditions (see Table 
4.2 and Schemes 4.6, 4.7, 4.9, and 4.10). Under the standard Tamao oxidation conditions, this 
observation is consistent with the model that we have previously devised for the tautomerization 
selectivity.17 For the more selective syn crotylation product, the larger vinyl group would be 
hindering approach to the front side of the enol by this model, while the less selective anti 
crotylation product would result in the smaller methyl group in the corresponding blocking 
position (Scheme 4.11).  
 
Scheme 4.11 Rationalized Model for Selectivity Trend Observed with Standard Tamao Oxidation Conditions 
  The corresponding effect for the “aprotic” Tamao is not as easily explained, since the 
origins of the observed syn-selectivity are not as clear. Indeed, in our attempts to expand the scope 
of these “aprotic” Tamao oxidation conditions from the substrate for which they were originally 
developed 4.31, it has become clear that there is a trend in the selectivity which is highly dependent 
on the substrate used. When decreasing the steric bulk of the R group in going from a quaternary 
carbon center as in 4.31, to R = Me for 4.22, and finally to R = H in 4.29, the selectivity drops 
significantly (Scheme 4.12), indicating that our current conditions are less general and more 




development of more general conditions for the syn-selective Tamao oxidation/diastereoselective 
tautomerization, which remains a long-term goal of the Leighton group. 
 
Scheme 4.12 Selectivity Trend for “Aprotic” Tamao Oxidation (shown for Syn, Anti Stereotriads) 
4.6 Demonstrated Application in Dictyostatin Analog Synthesis18 
Soon after our new stereotriad synthesis strategy had been developed, it became useful for 
a fellow group member to employ it in efforts to obtain fragment 4.32. This target fragment was 
simply the acetal-protected α-methyl linker analog of anti, syn aldehyde building block 4.26, which 
was to be used in the synthesis of a dictyostatin C12 linker analog (Scheme 4.13). In applying our  
newly developed conditions to terminal alkyne 4.33, the 1-pot silylformylation-crotylation 
sequence proceeded smoothly in 91% yield over the two steps to access intermediate 4.34. 
Utilizing the standard Tamao oxidation conditions provided the desired anti diastereoselectivity in 
>10:1 d.r. and after direct acetal protection of the crude aldehyde, the desired fragment 4.32 was 
obtained in 70% over two steps. This route provided a direct and stereoselective synthesis of the 





Scheme 4.13 Application of Our Route to Access Analog of Anti, Syn Stereotriad 
4.7 Conclusion 
We have developed an efficient synthetic strategy for the synthesis of a number of widely 
useful polyketide building blocks, rapidly generating three contiguous stereocenters with 
moderately good to excellent levels of selectivity. Though not yet a comprehensive strategy, our 
efforts thus far have resulted in the development of highly efficient syntheses of building blocks 
4.19, 4.20, 4.21, 4.26, and 4.27 which have been demonstrated on gram or multigram scale from 
2-butyne or propyne, with yields in the range of 53-63% over 3 steps (average of 80-86% per step) 
(Scheme 4.14).  
 




Further efforts to develop more generally useful conditions for syn-selective Tamao 
oxidation/diastereoselective tautomerization could allow improved access to the remaining 
building blocks 4.22, 4.28, and 4.29. By eliminating a number of protecting group manipulations 
and redox reactions, we have developed a scalable and more direct way to access a number of 
these fragments relative to previous approaches, such as the widely employed “Roche ester” 
strategy (Scheme 4.15). 
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4.9 Experimental Procedures and Characterization Data 
General Information. All reactions were carried out under an atmosphere of nitrogen in 
flame-dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) 
was carried out on glass-backed silica gel XHL TLC plates (250 μm) from Sorbent 
Technologies; visualization by UV light, p-anisaldehyde stain, phosphomolybdic acid stain, or 
potassium permanganate (KMnO4) stain. Gas chromatographic analyses were performed on a 
Hewlett-Packard 6890 Series Gas Chromatograph equipped with a capillary split-splitless inlet 
and flame ionization detector with electronic pneumatics control using a Supelco ß-Dex 325 (30 
m x 0.25 mm) capillary GLC column. 1H NMR spectra were recorded on a Bruker DPX-400 
(400 MHz) or a Bruker Avance III 500 (500 MHz) spectrometer and are reported in ppm from 
CDCl3 internal standard (7.26 ppm). Data are reported as follows: (bs= broad singlet, s = singlet, 
d = doublet, t = triplet, q = quartet, quin = quintet, sep = septet, m = multiplet, dd = doublet of 
doublets, ddd = doublet of doublet of doublets; coupling constant(s) in Hz; integration). Proton 
decoupled 13C NMR spectra were recorded on a Bruker Avance III 500 (125 MHz) spectrometer 
and are reported in ppm from CDCl3 internal standard (77.16 ppm). Infrared spectra were 
recorded on a Perkin-Elmer Spectrum Two (Diamond ATR) IR spectrometer. Optical rotations 
were recorded on a Jasco DIP-1000 digital polarimeter. 
 
Isopropoxydiphenylsilane 4.10c was prepared using a modified literature procedure.1 To 
a cooled (0°C) solution of diphenylchlorosilane (20.0 mL, 102 mmol) in CH2Cl2 (1000 mL) was 
                                                 
1 Kim, H.; Ho, S.; Leighton, J. L. J. Am. Chem. Soc. 2011, 133, 6517-6520. 
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added Et3N (21.3 mL, 153 mmol) followed by slow addition of i-PrOH (9.4 mL, 123 mmol). 
After 1 hour, the solvent was concentrated under reduced pressure. The residue was diluted with 
Et2O (400 mL) and vigorously stirred for 10 minutes. The heterogeneous mixture was filtered, 
rinsing with Et2O (200 mL). The filtrate was concentrated and the resulting oil vacuum distilled 
(bp ~100 °C @ ~0.5 mm Hg) to give isopropoxydiphenylsilane 4.10c (22.0 g, 89%) as a 
colorless oil. The 1H NMR spectroscopic data is in agreement with data reported in the 
literature.2 
 
A glass liner for a Parr bomb was charged with isopropoxydiphenylsilane 4.10c (5.25 g, 
21.7 mmol). The bomb was assembled and pressurized with CO to approximately 500 psi and 
then vented. This procedure was repeated two more times then the bomb was pressurized again 
to 500 psi and stirred for approximately fifteen minutes at ambient temperature. The bomb was 
opened and Rh(acac)(CO)2 (112 mg, 0.434 mmol) was added followed by 2-butyne (23.8 mmol, 
5.5 mL of 4.3 M solution in PhCN). The bomb was reassembled and pressurized to 500 psi with 
CO, and then heated to 60°C (oil bath, external temperature). After 24 hours, the bomb was 
cooled, and then carefully vented and opened. 1H NMR analysis of an aliquot indicated complete 
consumption of silane starting material and formation of product 4.11c in a 5:1 ratio with an 
unidentified silane-related impurity. This reaction solution was used directly in the following 
crotylation reaction. For characterization purposes, an analytically pure sample of 4.11c was 
obtained by flash chromatography (pH 7 buffered silica gel, 2% EtOAc/hexanes): 1H NMR (500 
                                                 
2 Horner, L.; Mathias, J. J. Organometallic Chem. 1985, 282, 155-174. 
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MHz, CDCl3) δ 10.18 (s, 1H), 7.63 (d, J = 7.7 Hz, 4H), 7.45 – 7.48 (m, 2H), 7.40 – 7.43 (m, 4H), 
4.17 – 3.99 (m, 1H), 2.01 (s, 3H), 1.93 (s, 3H), 1.12 (d, J = 6.1 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) δ 194.8, 157.1, 150.7, 135.2, 134.3, 130.4, 128.3, 67.1, 25.6, 20.6, 11.8; IR (neat): ʋ (cm-
1) 3399, 3069, 3049, 2971, 2916, 2072, 1675, 1589, 1428, 1370, 1256, 1113, 1017, 701, 540, 
509; LRMS (FAB+) calcd C20H25O2Si [M-H]-: 323.15, found 323.31. 
 
To a solution of the reaction mixture from aldehyde 4.11c formation in CH2Cl2 (220 mL) 
was added (S,S)-trans-crotylsilane reagent 4.16 (11.11 g, 19.5 mmol) and Sc(OTf)3 (428 mg, 
0.868 mmol)1,3. After 2 hours at ambient temperature, the reaction was cooled to 0°C and 
tetrabutylammonium fluoride (TBAF) trihydrate (6.14 g, 19.5 mmol) was added. After 1 hour, 
the mixture was concentrated and the residue purified via flash chromatography on silica gel 
(gradient of 100% hexanes to 2.5% EtOAc/hexanes) to afford 4.18 (4.63 g, 67% over 2 steps) as 
a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.63 (dd, J = 7.7, 1.2 Hz, 2H), 7.53 (dd, J = 7.7, 
1.2 Hz, 2H), 7.39 (m, 6H), 5.67 – 5.50 (m, 1H), 4.97 (d, J = 17.3 Hz, 1H), 4.85 (d, J = 10.3 Hz, 
1H), 4.70 (s, 1H), 2.62 (m, 1H), 1.84 (s, 3H), 1.76 (s, 3H), 1.22 (d, J = 6.9 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 153.6, 139.3, 135.6, 135.3, 135.0, 134.6, 130.2, 130.1, 128.0, 127.9, 127.2, 
114.9, 89.7, 41.6, 17.7, 13.4, 12.7; IR (neat): ʋ (cm-1) 3067, 2966, 2919, 2856, 1614, 1428, 1374, 
1114, 1008, 914, 840, 734, 704, 541, 514, 486; LRMS (APCI+) calcd C21H25OSi [M+H]+: 
321.16, found 320.62; [α]22D -98.3 (c 0.22, CHCl3). Chiral GC analysis of 4.20 (Supelco β-dex 
                                                 
3 Hackman, B. M.; Lombardi, P. J.; Leighton, J. L. Org. Lett. 2004, 6, 4375. 
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325, Isothermal 100°C, 1 mL/min) revealed that 4.18 was produced in 95% enantiomeric excess 
(ee). 
 
Utilizing the same procedure as above with (S,S)-cis-crotylsilane reagent 4.15, product 
4.17 (4.58 g, 70% over 2 steps) was isolated as a colorless oil.  1H NMR (500 MHz, CDCl3) δ 
7.63 (dd, J = 7.9, 1.4 Hz, 2H), 7.52 (dd, J = 7.9, 1.4 Hz, 2H), 7.47 – 7.43 (m, 1H), 7.43 – 7.37 
(m, 3H), 7.37 – 7.32 (m, 2H), 6.09 (ddd, J = 17.4, 10.3, 7.1 Hz, 1H), 5.13 – 5.08 (m, 1H), 5.08 – 
5.04 (m, 1H), 4.80 (s, 1H), 2.66 – 2.52 (m, 1H), 1.88 (d, J = 0.7 Hz, 3H), 1.79 (s, 3H), 0.76 (d, J 
= 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 153.1, 142.9, 135.5, 135.1, 135.0, 134.6, 130.2, 
130.2, 128.0, 127.9, 127.9, 113.8, 89.2, 40.9, 13.3, 12.8, 12.2; IR (neat): ʋ (cm-1) 3067, 2969, 
2912, 2854, 1613, 1428, 1374, 1332, 1113, 1004, 912, 863, 836, 798, 705, 514; LRMS (APCI+) 
calcd C21H25OSi [M+H]+: 321.16, found 320.61; [α]20D -26.7 (c 1.38, CHCl3). Chiral GC 
analysis of 4.19 (Supelco β-dex 325, Isothermal 100°C, 1 mL/min) revealed that 4.17 was 
produced in 93% enantiomeric excess (ee). 
 
To a cooled (0°C) solution of 4.18 (4.63 g, 14.4 mmol) in THF (72 mL) and i-PrOH (72 
mL) was added KF (3.35 g, 57.6 mmol) followed by 30% H2O2 aqueous solution (18.7 mL, 187 
mmol). After 4 hours, the solution was diluted with distilled water (50 mL) and extracted with 
Et2O (4 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over 
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MgSO4, filtered, and concentrated. Purification of the residue by flash chromatography on silica 
gel (20% EtOAc/hexanes) afforded the product 4.20 as a yellow oil (1.96 g, 87%) in 9:1 d.r. 1H 
NMR (500 MHz, CDCl3) δ 5.83 (ddd, J = 17.2, 10.4, 8.6 Hz, 1H), 5.10 (m, 1H), 5.09 – 5.05 (m, 
1H), 3.60 (dd, J = 7.4, 3.5 Hz, 1H), 2.68 (m, 1H), 2.52 (s, 1H), 2.41 – 2.29 (m, 1H), 2.19 (s, 3H), 
1.12 (d, J = 7.4 Hz, 3H), 1.11 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 214.1, 139.0, 
116.1, 77.0, 50.2, 41.0, 29.9, 17.8, 14.0; IR (neat): ʋ (cm-1) 3446, 3073, 2970, 2931, 2876, 1704, 
1641, 1456, 1421, 1356, 1239, 1121, 1001, 962, 915, 702, 582, 498; LRMS (APCI+) calcd 
C9H17O2 [M+H]+: 157.12, found 156.93; [α]21D +0.7 (c 1.27, CHCl3). 
 
Utilizing the same procedure as above, product 4.19 was isolated (1.87 g, 84%) as a 
yellow oil in 18:1 d.r. 1H NMR (500 MHz, CDCl3) δ 5.85 – 5.70 (m, 1H), 5.07 (d, J = 0.7 Hz, 
1H), 5.05 (m, 1H), 3.46 (q, J = 5.8 Hz, 1H), 2.80 (qd, J = 7.2, 5.6 Hz, 1H), 2.68 (d, J = 6.7 Hz, 
1H), 2.33 (m, 1H), 2.19 (s, 3H), 1.18 (d, J = 7.3 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 214.9, 141.7, 115.3, 77.3, 48.4, 42.0, 30.3, 14.6, 14.6; IR (neat): ʋ (cm-1) 
3449, 3076, 2972, 2933, 2881, 1702, 1641, 1456, 1418, 1356, 1238, 1170, 1108, 1066, 998, 968, 
915, 699, 496; LRMS (APCI+) calcd C9H17O2 [M+H]+: 157.12, found 156.93; [α]21D +18.8 (c 
0.90, CHCl3). 
 
To a flask containing trimethylhydroquinone (473mg, 3.11 mmol), quinuclidine•HCl 
(367 mg, 2.49 mmol), and AgF (345 mg, 2.72 mmol) was added 4.17 (249 mg, 0.777 mmol) as a 
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solution in PhCN (15.5 mL). The solution was purged with O2, and then the reaction was stirred 
under an atmosphere of O2 (balloon). After 10 hours at room temperature, the reaction was 
diluted with CHCl3 (15 mL). The solution was filtered through Celite then washed with distilled 
water (10 mL). The aqueous layer was extracted with CHCl3 (3 x 15 mL). The combined 
organics were washed with brine, dried over MgSO4, filtered, and concentrated. The residue was 
purified via flash chromatography on silica gel (gradient of 10% EtOAc/hexanes to 20% 
EtOAc/hexanes) to give 4.21 (90 mg, 75%) as an orange oil with 6:1 diastereomeric ratio (d.r.) 
with respect to the newly formed stereocenter. 1H NMR (500 MHz, CDCl3) δ 5.61 (ddd, J = 
17.2, 10.2, 8.9 Hz, 1H), 5.09 (dd, J = 17.2, 0.8 Hz, 1H), 5.02 (dd, J = 10.3, 1.6 Hz, 1H), 3.72 (dd, 
J = 9.1, 2.6 Hz, 1H), 2.71 (qd, J = 7.3, 2.7 Hz, 1H), 2.28 (d, J = 8.9 Hz, 1H), 2.19 (s, 3H), 1.14 
(d, J = 7.2 Hz, 3H), 1.12 (d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 214.3, 140.7, 115.5, 
73.9, 48.7, 41.7, 29.0, 17.2, 9.2; IR (neat): ʋ (cm-1) 3444, 2923, 2853, 1701, 1641, 1456, 1420, 
1358, 1260, 1087, 999, 981, 916, 796, 682, 505; LRMS (APCI+) calcd C9H17O2 [M+H]+: 
157.12, found 157.55; [α]21D -23.7 (c 0.32, CHCl3). 
 
Utilizing the same procedure as above (24 hr reaction time), product 4.22 (57 mg, 71%) 
was isolated as an orange oil with 3:1 diastereomeric ratio (d.r.) with respect to the newly formed 
stereocenter. 1H NMR (500 MHz, CDCl3) δ 5.80 (ddd, J = 16.0, 11.4, 8.4 Hz, 1H), 5.14 (s, 1H), 
5.13 – 5.09 (m, 1H), 3.73 (dd, J = 7.7, 3.9 Hz, 1H), 2.70 – 2.63 (m, 1H), 2.29 – 2.23 (m, 1H), 
2.21 (s, 3H), 1.16 (d, J = 7.1 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
212.9, 140.8, 116.5, 74.5, 48.9, 41.8, 29.0, 16.8, 10.0; IR (neat): ʋ (cm-1) 3451, 3082, 2970, 
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2926, 1704, 1644, 1456, 1430, 1357, 1267, 1133, 998, 916, 741, 698, 498; LRMS (APCI+) calcd 
C9H17O2 [M+H]+: 157.12, found 157.60; [α]19D -20.9 (c 0.11, CHCl3). 
 
To a cooled (-78°C) glass liner for a Parr bomb charged with isopropoxydiphenylsilane 
4.10c (1.03 g, 4.25 mmol) was added propyne (~0.7 mL, ~13 mmol, condensed into a cooled (-
78°C) pre-marked vial) via cannula, followed by benzene (4.2 mL). Once the solution was 
frozen, Rh(acac)(CO)2 (11 mg, 0.0425 mmol) was added on top. The bomb was assembled and 
pressurized to 300 psi with CO, and then allowed to warm to ambient temperature and begin 
stirring. After 5 hours, the bomb was carefully vented and opened. 1H NMR analysis of an 
aliquot indicated complete consumption of silane starting material and formation of product 4.23. 
This reaction solution was used directly in the following crotylation reaction. For 
characterization purposes, an analytically pure sample of 4.23 was obtained by flash 
chromatography (pH 7 buffered silica gel, 2% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3) δ 
10.04 (s, 1H), 7.70 – 7.59 (m, 4H), 7.49 – 7.35 (m, 6H), 7.10 (s, 1H), 4.13 (hept, J = 6.0 Hz, 1H), 
2.01 (d, J = 0.7 Hz, 3H), 1.16 (d, J = 6.1 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 194.7, 155.1, 
145.5, 134.9, 134.8, 130.4, 128.3, 66.9, 25.7, 19.0; IR (neat): ʋ (cm-1) 2973, 1689, 1592, 1428, 
1371, 1318, 1112, 1020, 879, 833, 733, 702, 511; LRMS (FAB+) calcd C19H22O2SiNa [M+Na]+: 




To a solution of the reaction mixture from aldehyde 4.23 formation in CH2Cl2 (42.5 mL) 
was added (S,S)-cis-crotylsilane reagent 4.15 (2.66 g, 4.68 mmol) and Sc(OTf)3 (84 mg, 0.170 
mmol). After 1.5 hours at ambient temperature, the reaction was cooled to 0°C, and then 
tetrabutylammonium fluoride (TBAF) trihydrate (1.34 g, 4.25 mmol) was added. After 1 hour, 
the mixture was concentrated and the residue purified via flash chromatography on silica gel 
(gradient of 100% heaxanes to 2% EtOAc/hexanes) to afford 4.24 (1.18 g, 91% over 2 steps) as a 
colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 6.8 Hz, 2H), 7.52 (d, J = 6.8 Hz, 2H), 
7.47 – 7.29 (m, 6H), 6.08 (ddd, J = 17.4, 10.3, 7.1 Hz, 1H), 5.98 (s, 1H), 5.10 (d, J = 17.3 Hz, 
1H), 5.06 (d, J = 10.3 Hz, 1H), 4.81 (s, 1H), 2.56 (dq, J = 7.1, 6.9 Hz, 1H), 1.97 (s, 3H), 0.77 (d, 
J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 163.5, 142.6, 135.8, 135.1, 135.0, 134.8, 130.2, 
128.5, 127.9, 127.9, 121.1, 114.0, 88.9, 40.7, 19.3, 12.2; IR (neat): ʋ (cm-1) 3068, 2972, 2849, 
1587, 1428, 1113, 1015, 973, 822, 738, 699, 528, 491; LRMS (APCI+) calcd C20H23OSi 
[M+H]+: 307.14, found 306.85; [α]19D -34.7 (c 1.48, CHCl3). Chiral GC analysis of 4.26 
(Supelco β-dex 325, Isothermal 80°C, 1 mL/min) revealed that 4.24 was produced in 96% 




Utilizing the same procedure as above, product 4.25 (1.02 g, 86% over 2 steps) was 
isolated as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 7.9, 1.4 Hz, 2H), 7.54 (dd, 
J = 7.9, 1.4 Hz, 2H), 7.47 – 7.30 (m, 6H), 5.91 (s, 1H), 5.58 (ddd, J = 17.4, 10.3, 8.0 Hz, 1H), 
4.99 (ddd, J = 17.3, 1.8, 1.2 Hz, 1H), 4.86 (dd, J = 10.3, 1.2 Hz, 1H), 4.71 (s, 1H), 2.60 (pd, J = 
8.0, 2.2 Hz, 1H), 1.95 (s, 3H), 1.22 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.0, 
138.9, 136.0, 135.3, 135.0, 130.2, 127.9, 127.8, 125.1, 120.4, 115.1, 89.3, 41.7, 19.3, 17.8; IR 
(neat): ʋ (cm-1) 3068, 2974, 1747, 1587, 1428, 1116, 1016, 953, 809, 738, 699, 528, 492; LRMS 
(APCI+) calcd C20H23OSi [M+H]+: 307.14, found 306.83; [α]19D -95.9 (c 1.56, CHCl3). Chiral 
GC analysis of 4.27 (Supelco β-dex 325, Isothermal 90°C, 1 mL/min) revealed that 4.25 was 
produced in 99% enantiomeric excess (ee). 
 
To a cooled (0°C) solution of 4.24 (519 mg, 1.69 mmol) in i-PrOH (16.9 mL) was added 
KHCO3 (169 mg, 1.69 mmol) followed by 30% H2O2 aqueous solution (2.24 mL, 22.0 mmol). 
After 2 hours, the solution was diluted with distilled water (6 mL) and extracted with DCM (4 x 
10 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered, and 
concentrated. Purification of the residue by flash chromatography (pH 7 buffered silica gel, 15% 
EtOAc/hexanes) afforded the product 4.26 as a yellow oil (167 mg, 69%) in >20:1 d.r. 1H NMR 
(400 MHz, CDCl3) δ 9.78 (d, J = 1.8 Hz, 1H), 5.90 – 5.71 (m, 1H), 5.14 (d, J = 1.1 Hz, 1H), 5.12 
– 5.10 (m, 1H), 3.71 – 3.59 (m, 1H), 2.67 – 2.59 (m, 1H), 2.52 – 2.40 (m, 1H), 2.11 (d, J = 5.0 
Hz, 1H), 1.14 (d, J = 7.3 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H);  13C NMR (125 MHz, CDCl3) δ 
205.5, 140.9, 116.0, 75.9, 49.1, 40.8, 13.4, 11.2; IR (neat): ʋ (cm-1) 3448, 2974, 2880, 1717, 
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1640, 1456, 1376, 1232, 1078, 996, 917,756, 679; LRMS (FAB+) calcd C8H14O2 [M+H]+: 
143.10, found 143.13; [α]19D -7.9 (c 0.59, CHCl3).   
 
To a cooled (0°C) solution of 4.25 (501 mg, 1.63 mmol) in THF (8.2 mL) and i-PrOH 
(8.2 mL) was added KHCO3 (171 mg, 1.71 mmol) followed by 30% H2O2 aqueous solution (2.1 
mL, 21.2 mmol). After 4 hours, the solution was diluted with distilled water (6 mL) and 
extracted with DCM (4 x 10 mL). The combined organic layers were washed with brine, dried 
over MgSO4, filtered, and concentrated. Purification of the residue by flash chromatography (pH 
7 buffered silica gel, 15% EtOAc/hexanes) afforded the product 4.27 as a yellow oil (159 mg, 
69%) in 17:1 d.r. 1H NMR (400 MHz, CDCl3) δ 9.77 (d, J = 2.0 Hz, 1H), 5.80 (ddd, J = 17.0, 
10.5, 8.6 Hz, 1H), 5.17 – 5.15 (m, 1H), 5.15 – 5.10 (m, 1H), 3.65 – 3.62 (m, 1H), 2.55 – 2.51 (m, 
1H), 2.43 – 2.37 (m, 1H), 2.31 (d, J = 3.1 Hz, 1H), 1.15 (d, J = 7.3 Hz, 3H), 1.11 (d, J = 6.9 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 205.8, 138.9, 117.1, 76.0, 49.7, 41.3, 17.3, 11.0; IR (neat): ʋ 
(cm-1) 3429, 2966, 2928, 2878, 1719, 1639, 1456, 1376, 1097, 997, 967, 915, 569; LRMS 
(FAB+) calcd C8H14O2 [M+H]+: 143.10, found 143.10; [α]19D +13.1 (c 0.72, CHCl3). 
Stereochemical Proofs.  
 For β-hydroxyketone 4.20, the proof was achieved by carrying out Narasaka’s syn-
selective reduction using Prasad’s protocol4 followed by acetonide protection as shown in 
Scheme 1. Rychnovsky 13C NMR analysis5 confirmed that the acetonide possessed the 1,3-syn 
stereochemistry. Analysis of the acetonide by COSY and NOESY NMR established the relative 
stereochemistry of the methyl-bearing stereocenter set in the “standard” Tamao oxidation via the 
                                                 
4 Chen, K.-M.; Hardtmann, K.; Prasad, K.; Repič, O.; Shapiro, M.J. Tetrahedron Lett. 1987, 28, 155-158. 
5 Rychnovsky, S. D.; Rogers, B.; Yang, G. J. Org. Chem. 1993, 58, 3511. 
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key nOe interactions indicated. Since 4.20 and 4.22 are derived from the same starting material 
4.18 (with two of the stereocenters already established), the two compounds represent 
diastereomers at the α-methyl stereocenter and the stereochemistry of 4.22 must be as assigned. 
 For β-hydroxyketone 4.19, the proof was achieved by carrying out a TBS protection to 
intercept previously characterized compound 4.35,6 verified by 1H NMR. Since 4.19 and 4.21 are 
derived from the same starting material 4.17 (with two of the stereocenters already established), 
the two compounds represent diastereomers at the α-methyl stereocenter and the stereochemistry 
of 4.21 must be as assigned.  
 
For β-hydroxyaldehyde 4.26, the proof was achieved by carrying out a sodium 
borohydride reduction to intercept previously characterized compound 4.36,7,8 verified by 1H and 
13C NMR. For β-hydroxyaldehyde 4.27, the proof was achieved by carrying out a sodium 
borohydride reduction to intercept 4.37, the enantiomer of a previously characterized 
compound,5 verified by 1H and 13C NMR with the opposite sign in the optical rotation. 
            
                                                 
6 McGarvey, G. J.; Williams, J.M.; Hiner, R.N., Matsubara, Y.; Oh, T. J. Am. Chem. Soc. 1986, 108, 4943-4952. 
7 Mulzer, J. ; Autenrieth-Ansorge, L. ; Kirstein, H. ; Matsuoka, T. ; Münch, W. J. Org. Chem. 1987, 52, 3784-3789. 
8 Marshall, J. A.; Palovich, M.R. J. Org. Chem. 1998, 63, 4381-4384. 
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4.11 GC Traces 
Chiral GC analysis of 4.19 (product of “standard” Tamao oxidation) revealed that 
4.17 was produced in 93% enantiomeric excess (ee). 
 
 




Chiral GC analysis of 4.20 (product of “standard” Tamao oxidation) revealed that 
4.18 was produced in 95% enantiomeric excess (ee). 
 
 
Supelco β-dex 325, Isothermal 100°C, 1 mL/min 
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Chiral GC analysis of 4.26 (product of “standard” Tamao oxidation) revealed that 









Chiral GC analysis of 4.27 (product of “standard” Tamao oxidation) revealed that 
4.25 was produced in 99% enantiomeric excess (ee). 
 
Supelco β-dex 325, Isothermal 90°C, 1 mL/min 
 
 
